{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:19:54Z","timestamp":1773674394364,"version":"3.50.1"},"reference-count":369,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s11010-023-04715-1","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T18:02:49Z","timestamp":1680631369000},"page":"127-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors"],"prefix":"10.1007","volume":"479","author":[{"given":"Swati","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmal Kumar","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"4715_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.21037\/cco.2017.05.02","volume":"6","author":"PN Harter","year":"2017","unstructured":"Harter PN, Braun Y, Plate KH (2017) Classification of meningiomas-advances and controversies. Chin Clin Oncol 6:S2. https:\/\/doi.org\/10.21037\/cco.2017.05.02","journal-title":"Chin Clin Oncol"},{"key":"4715_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol 17:iv1\u2013iv62. https:\/\/doi.org\/10.1093\/neuonc\/nov189","journal-title":"Neuro Oncol"},{"issue":"1","key":"4715_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000084858","volume":"41","author":"K Tufan","year":"2005","unstructured":"Tufan K, Dogulu F, Kurt G, Emmez H, Ceviker N, Baykaner MK (2005) Intracranial meningiomas of childhood and adolescence. Pediatr Neurosurg 41(1):1\u20137. https:\/\/doi.org\/10.1159\/000084858","journal-title":"Pediatr Neurosurg"},{"key":"4715_CR4","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/nov297","volume":"18","author":"QT Ostrom","year":"2016","unstructured":"Ostrom QT, Gittleman H, De Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C (2016) American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol 18:i1-50","journal-title":"Neuro Oncol"},{"issue":"6","key":"4715_CR5","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ijc.21255","volume":"117","author":"L Klaeboe","year":"2005","unstructured":"Klaeboe L, Lonn S, Scheie D, Auvinen A, Christensen HC, Feychting M, Johansen C, Salminen T, Tynes T (2005) Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968\u20131997. Int J Cancer 117(6):996\u20131001. https:\/\/doi.org\/10.1002\/ijc.21255","journal-title":"Int J Cancer"},{"issue":"5","key":"4715_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cdp.2005.07.002","volume":"29","author":"B Schneider","year":"2005","unstructured":"Schneider B, P\u00fclhorn H, R\u00f6hrig B, Rainov NG (2005) Predisposing conditions and risk factors for development of symptomatic meningioma in adults. Cancer Detect Prevent. 29(5):440\u2013447. https:\/\/doi.org\/10.1016\/j.cdp.2005.07.002","journal-title":"Cancer Detect Prevent."},{"issue":"3","key":"4715_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/neuonc\/noq201","volume":"13","author":"P Flint-Richter","year":"2011","unstructured":"Flint-Richter P, Mandelzweig L, Oberman B, Sadetzki S (2011) Possible interaction between ionizing radiation, smoking, and gender in the causation of meningioma. Neuro Oncol 13(3):345\u2013352. https:\/\/doi.org\/10.1093\/neuonc\/noq201","journal-title":"Neuro Oncol"},{"issue":"1","key":"4715_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","volume":"20","author":"D Simpson","year":"1957","unstructured":"Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20(1):22. https:\/\/doi.org\/10.1136\/jnnp.20.1.22","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"4715_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3171\/2015.9.JNS15754","volume":"125","author":"K Gousias","year":"2016","unstructured":"Gousias K, Schramm J, Simon M (2016) The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg 125(3):551\u2013560. https:\/\/doi.org\/10.3171\/2015.9.JNS15754","journal-title":"J Neurosurg"},{"issue":"6","key":"4715_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/neuonc\/not330","volume":"16","author":"T Kaley","year":"2014","unstructured":"Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P (2014) Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: a RANO review. Neuro Oncol 16(6):829\u2013840. https:\/\/doi.org\/10.1093\/neuonc\/not330","journal-title":"Neuro Oncol"},{"issue":"4","key":"4715_CR11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3171\/2018.6.JNS18118","volume":"131","author":"ST Magill","year":"2018","unstructured":"Magill ST, Dalle Ore CL, Diaz MA, Jalili DD, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW (2018) Surgical outcomes after reoperation for recurrent non\u2013skull base meningiomas. J Neurosurg 131(4):1179\u20131187. https:\/\/doi.org\/10.3171\/2018.6.JNS18118","journal-title":"J Neurosurg"},{"issue":"490","key":"4715_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.canlet.2020.06.015","volume":"10","author":"O Camuzard","year":"2020","unstructured":"Camuzard O, Santucci-Darmanin S, Carle GF, Pierrefite-Carle V (2020) Autophagy in the crosstalk between tumor and microenvironment. Cancer Lett 10(490):143\u2013153. https:\/\/doi.org\/10.1016\/j.canlet.2020.06.015","journal-title":"Cancer Lett"},{"issue":"1","key":"4715_CR13","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.3402\/jev.v4.27066","volume":"4","author":"M Y\u00e1\u00f1ez-M\u00f3","year":"2015","unstructured":"Y\u00e1\u00f1ez-M\u00f3 M, Siljander PR, Andreu Z, Bedina Zavec A, Borr\u00e0s FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Col\u00e1s E (2015) Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 4(1):27066","journal-title":"J Extracell Vesicles."},{"key":"4715_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2125656","author":"H Wang","year":"2020","unstructured":"Wang H, Wang L, Zhou X, Luo X, Liu K, Jiang E, Chen Y, Shao Z, Shang Z (2020) OSCC exosomes regulate miR-210\u20133p targeting EFNA3 to promote oral cancer angiogenesis through the PI3K\/AKT pathway. BioMed Res Int. https:\/\/doi.org\/10.1155\/2020\/2125656","journal-title":"BioMed Res Int"},{"issue":"21","key":"4715_CR15","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1038\/s41388-018-0183-6","volume":"37","author":"L Bao","year":"2018","unstructured":"Bao L, You BO, Shi SI, Shan Y, Zhang Q, Yue H, Zhang J, Zhang W, Shi Y, Liu Y, Wang X (2018) Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10. Oncogene 37(21):2873\u20132889. https:\/\/doi.org\/10.1038\/s41388-018-0183-6","journal-title":"Oncogene"},{"issue":"6","key":"4715_CR16","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1038\/oncsis.2017.52","volume":"6","author":"Y Yang","year":"2017","unstructured":"Yang Y, Liu Q, Lu J, Adah D, Yu S, Zhao S, Yao Y, Qin L, Chen X (2017) Exosomes from Plasmodium-infected hosts inhibit tumor angiogenesis in a murine Lewis lung cancer model. Oncogenesis 6(6):e351. https:\/\/doi.org\/10.1038\/oncsis.2017.52","journal-title":"Oncogenesis"},{"issue":"1","key":"4715_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-020-00535-8","volume":"18","author":"JY Xie","year":"2020","unstructured":"Xie JY, Wei JX, Lv LH, Han QF, Yang WB, Li GL, Wang PX, Wu SB, Duan JX, Zhuo WF, Liu PQ (2020) Angiopoietin-2 induces angiogenesis via exosomes in human hepatocellular carcinoma. Cell Commun Signal 18(1):1\u20133","journal-title":"Cell Commun Signal"},{"issue":"8","key":"4715_CR18","doi-asserted-by":"publisher","first-page":"12831","DOI":"10.18632\/oncotarget.14606","volume":"8","author":"X Dai","year":"2017","unstructured":"Dai X, Wang L, Deivasigamni A, Looi CY, Karthikeyan C, Trivedi P, Chinnathambi A, Alharbi SA, Arfuso F, Dharmarajan A, Goh BC (2017) A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. Oncotarget 8(8):12831. https:\/\/doi.org\/10.18632\/oncotarget.14606","journal-title":"Oncotarget"},{"key":"4715_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fphar.2016.00395","volume":"7","author":"PS Ong","year":"2016","unstructured":"Ong PS, Wang LZ, Dai X, Tseng SH, Loo SJ, Sethi G (2016) Judicious toggling of mTOR activity to combat insulin resistance and cancer: current evidence and perspectives. Front Pharmacol 7:395. https:\/\/doi.org\/10.3389\/fphar.2016.00395","journal-title":"Front Pharmacol"},{"issue":"49","key":"4715_CR20","doi-asserted-by":"publisher","first-page":"34296","DOI":"10.1074\/jbc.M114.601104","volume":"289","author":"CD Mohan","year":"2014","unstructured":"Mohan CD, Bharathkumar H, Bulusu KC, Pandey V, Rangappa S, Fuchs JE, Shanmugam MK, Dai X, Li F, Deivasigamani A, Hui KM (2014) Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. J Biol Chem 289(49):34296\u201334307. https:\/\/doi.org\/10.1074\/jbc.M114.601104","journal-title":"J Biol Chem"},{"issue":"3","key":"4715_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00109-013-1095-0","volume":"92","author":"KA Manu","year":"2014","unstructured":"Manu KA, Shanmugam MK, Li F, Chen L, Siveen KS, Ahn KS, Kumar AP, Sethi G (2014) Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J Mol Med 92(3):267\u2013276. https:\/\/doi.org\/10.1007\/s00109-013-1095-0","journal-title":"J Mol Med"},{"issue":"4","key":"4715_CR22","doi-asserted-by":"publisher","first-page":"e3010","DOI":"10.1002\/jgm.3010","volume":"20","author":"SC Tan","year":"2018","unstructured":"Tan SC (2018) Low penetrance genetic polymorphisms as potential biomarkers for colorectal cancer predisposition. J Gene Med 20(4):e3010","journal-title":"J Gene Med"},{"key":"4715_CR23","doi-asserted-by":"publisher","first-page":"620603","DOI":"10.3389\/fcell.2020.620603","volume":"8","author":"H Wang","year":"2021","unstructured":"Wang H, Wang L, Pan H, Wang Y, Shi M, Yu H, Wang C, Pan X, Chen Z (2021) Exosomes derived from macrophages enhance aerobic glycolysis and chemoresistance in lung cancer by stabilizing c-Myc via the inhibition of NEDD4L. Front Cell Develop Biol. 8:620603. https:\/\/doi.org\/10.3389\/fcell.2020.620603","journal-title":"Front Cell Develop Biol."},{"issue":"6","key":"4715_CR24","doi-asserted-by":"publisher","first-page":"8442","DOI":"10.1096\/fj.201902186R","volume":"34","author":"T Shen","year":"2020","unstructured":"Shen T, Huang Z, Shi C, Pu X, Xu X, Wu Z, Ding G, Cao L (2020) Pancreatic cancer-derived exosomes induce apoptosis of T lymphocytes through the p38 MAPK-mediated endoplasmic reticulum stress. FASEB J 34(6):8442\u20138458. https:\/\/doi.org\/10.1096\/fj.201902186R","journal-title":"FASEB J"},{"issue":"7","key":"4715_CR25","first-page":"2485","volume":"12","author":"B Wang","year":"2019","unstructured":"Wang B, Wang Y, Yan Z, Sun Y, Su C (2019) Colorectal cancer cell-derived exosomes promote proliferation and decrease apoptosis by activating the ERK pathway. Int J Clin Exp Pathol 12(7):2485","journal-title":"Int J Clin Exp Pathol"},{"key":"4715_CR26","doi-asserted-by":"publisher","first-page":"601953","DOI":"10.3389\/fcell.2020.601953","volume":"8","author":"L Wang","year":"2020","unstructured":"Wang L, Xu P, Xie X, Hu F, Jiang L, Hu R, Ding F, Xiao H, Zhang H (2020) Down regulation of SIRT2 Reduced ASS induced NSCLC apoptosis through the release of autophagy components via exosomes. Front Cell Develop Biol. 8:601953. https:\/\/doi.org\/10.3389\/fcell.2020.601953","journal-title":"Front Cell Develop Biol."},{"issue":"10","key":"4715_CR27","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/biom10101406","volume":"10","author":"ST Hwang","year":"2020","unstructured":"Hwang ST, Yang MH, Kumar AP, Sethi G, Ahn KS (2020) Corilagin represses epithelial to mesenchymal transition process through modulating Wnt\/\u03b2-catenin signaling cascade. Biomolecules 10(10):1406. https:\/\/doi.org\/10.3390\/biom10101406","journal-title":"Biomolecules"},{"issue":"8","key":"4715_CR28","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.3390\/molecules24081584","volume":"24","author":"MH Yang","year":"2019","unstructured":"Yang MH, Lee JH, Ko JH, Jung SH, Sethi G, Ahn KS (2019) Brassinin represses invasive potential of lung carcinoma cells through deactivation of PI3K\/Akt\/mTOR signaling cascade. Molecules 24(8):1584. https:\/\/doi.org\/10.3390\/molecules24081584","journal-title":"Molecules"},{"issue":"7","key":"4715_CR29","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/molecules23071601","volume":"23","author":"JH Ko","year":"2018","unstructured":"Ko JH, Nam D, Um JY, Jung SH, Sethi G, Ahn KS (2018) Bergamottin suppresses metastasis of lung cancer cells through abrogation of diverse oncogenic signaling cascades and epithelial-to-mesenchymal transition. Molecules 23(7):1601. https:\/\/doi.org\/10.3390\/molecules23071601","journal-title":"Molecules"},{"issue":"8","key":"4715_CR30","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3390\/cancers12082300","volume":"12","author":"R Gaballa","year":"2020","unstructured":"Gaballa R, Ali HE, Mahmoud MO, Rhim JS, Ali HI, Salem HF, Saleem M, Kandeil MA, Ambs S, Abd Elmageed ZY (2020) Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate Cancer cells by inducing epithelial-mesenchymal transition. Cancers 12(8):2300. https:\/\/doi.org\/10.3390\/cancers12082300","journal-title":"Cancers"},{"issue":"2","key":"4715_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03490-5","volume":"12","author":"J Cai","year":"2021","unstructured":"Cai J, Gong L, Li G, Guo J, Yi X, Wang Z (2021) Exosomes in ovarian cancer ascites promote epithelial\u2013mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p. Cell Death Dis 12(2):1\u20137. https:\/\/doi.org\/10.1038\/s41419-021-03490-5","journal-title":"Cell Death Dis"},{"issue":"3","key":"4715_CR32","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s12015-020-10089-4","volume":"17","author":"S Shojaei","year":"2021","unstructured":"Shojaei S, Hashemi SM, Ghanbarian H, Sharifi K, Salehi M, Mohammadi-Yeganeh S (2021) Delivery of miR-381\u20133p mimic by mesenchymal stem cell-derived exosomes inhibits triple negative breast cancer aggressiveness; an in vitro study. Stem Cell Rev Rep. 17(3):1027\u20131038. https:\/\/doi.org\/10.1007\/s12015-020-10089-4","journal-title":"Stem Cell Rev Rep."},{"issue":"7","key":"4715_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/cancers10070228","volume":"10","author":"J Monisha","year":"2018","unstructured":"Monisha J, Roy NK, Padmavathi G, Banik K, Bordoloi D, Khwairakpam AD, Arfuso F, Chinnathambi A, Alahmadi TA, Alharbi SA, Sethi G (2018) NGAL is downregulated in oral squamous cell carcinoma and leads to increased survival, proliferation, migration and chemoresistance. Cancers 10(7):228. https:\/\/doi.org\/10.3390\/cancers10070228","journal-title":"Cancers"},{"issue":"10","key":"4715_CR34","doi-asserted-by":"publisher","first-page":"18249","DOI":"10.1002\/jcp.28456","volume":"234","author":"JH Ko","year":"2019","unstructured":"Ko JH, Um JY, Lee SG, Yang WM, Sethi G, Ahn KS (2019) Conditioned media from adipocytes promote proliferation, migration, and invasion in melanoma and colorectal cancer cells. J Cell Physiol 234(10):18249\u201318261. https:\/\/doi.org\/10.1002\/jcp.28456","journal-title":"J Cell Physiol"},{"issue":"11","key":"4715_CR35","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1080\/09168451.2016.1200456","volume":"80","author":"R Kothapalli","year":"2016","unstructured":"Kothapalli R, Sivaraman Siveen K, Tan TZ, Thiery JP, Kumar AP, Sethi G, Swaminathan K (2016) Functional characterization of selective exosite-binding inhibitors of matrix metalloproteinase-13 (MMP-13)\u2013experimental validation in human breast and colon cancer. Biosci Biotechnol Biochem 80(11):2122\u20132131. https:\/\/doi.org\/10.1080\/09168451.2016.1200456","journal-title":"Biosci Biotechnol Biochem"},{"issue":"5","key":"4715_CR36","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/ijms18051095","volume":"18","author":"H Lee","year":"2017","unstructured":"Lee H, Baek SH, Lee JH, Kim C, Ko JH, Lee SG, Chinnathambi A, Alharbi SA, Yang WM, Um JY, Sethi G (2017) Isorhynchophylline, a potent plant alkaloid, induces apoptotic and anti-metastatic effects in human hepatocellular carcinoma cells through the modulation of diverse cell signaling cascades. Int J Mol Sci 18(5):1095. https:\/\/doi.org\/10.3390\/ijms18051095","journal-title":"Int J Mol Sci"},{"key":"4715_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3389\/fphar.2018.00531","volume":"9","author":"YY Jung","year":"2018","unstructured":"Jung YY, Lee JH, Nam D, Narula AS, Namjoshi OA, Blough BE, Um JY, Sethi G, Ahn KS (2018) Anti-myeloma effects of icariin are mediated through the attenuation of JAK\/STAT3-dependent signaling cascade. Front Pharmacol 9:531. https:\/\/doi.org\/10.3389\/fphar.2018.00531","journal-title":"Front Pharmacol"},{"issue":"6","key":"4715_CR38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11864-004-0038-y","volume":"5","author":"KP McMullen","year":"2004","unstructured":"McMullen KP, Stieber VW (2004) Meningioma: current treatment options and future directions. Curr Treat Options Oncol 5(6):499\u2013509. https:\/\/doi.org\/10.1007\/s11864-004-0038-y","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"4715_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/01.jnen.0000189834.63951.81","volume":"64","author":"M Johnson","year":"2005","unstructured":"Johnson M, Toms S (2005) Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol 64(12):1029\u20131036. https:\/\/doi.org\/10.1097\/01.jnen.0000189834.63951.81","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"4715_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/s-2007-1003925","volume":"18","author":"J Jagannathan","year":"2008","unstructured":"Jagannathan J, Oskouian RJ, Yeoh HK, Saulle D, Dumont AS (2008) Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature. Skull Base. 18(3):173. https:\/\/doi.org\/10.1055\/s-2007-1003925","journal-title":"Skull Base."},{"issue":"12","key":"4715_CR41","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(06)70625-1","volume":"5","author":"MJ Riemenschneider","year":"2006","unstructured":"Riemenschneider MJ, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5(12):1045\u20131054. https:\/\/doi.org\/10.1016\/S1474-4422(06)70625-1","journal-title":"Lancet Neurol"},{"issue":"2","key":"4715_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/107327480301000206","volume":"10","author":"B Ragel","year":"2003","unstructured":"Ragel B, Jensen RL (2003) New approaches for the treatment of refractory meningiomas. Cancer Control 10(2):148\u2013158. https:\/\/doi.org\/10.1177\/107327480301000206","journal-title":"Cancer Control"},{"issue":"1","key":"4715_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11060-007-9434-z","volume":"86","author":"MD Johnson","year":"2008","unstructured":"Johnson MD, Sade B, Milano MT, Lee JH, Toms SA (2008) New prospects for management and treatment of inoperable and recurrent skull base meningiomas. J Neuro-Oncol 86(1):109\u2013122. https:\/\/doi.org\/10.1007\/s11060-007-9434-z","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"4715_CR44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1227\/01.NEU.0000255421.78431.AE","volume":"60","author":"M Simon","year":"2007","unstructured":"Simon M, Bostr\u00f6m JP, Hartmann C (2007) Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 60(5):787\u2013798","journal-title":"Neurosurgery"},{"issue":"7","key":"4715_CR45","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","volume":"62","author":"MC Chamberlain","year":"2004","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62(7):1210\u20131212. https:\/\/doi.org\/10.1212\/01.WNL.0000118300.82017.F4","journal-title":"Neurology"},{"issue":"3","key":"4715_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3171\/jns.2007.106.3.455","volume":"106","author":"V Gupta","year":"2007","unstructured":"Gupta V, Su YS, Samuelson CG, Liebes LF, Chamberlain MC, Hofman FM, Sch\u00f6nthal AH, Chen TC (2007) Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg 106(3):455\u2013462. https:\/\/doi.org\/10.3171\/jns.2007.106.3.455","journal-title":"J Neurosurg"},{"issue":"4","key":"4715_CR47","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/foc.1997.2.4.11","volume":"2","author":"UM Schrell","year":"1997","unstructured":"Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, Fahlbusch R (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. Neurosurg Focus 2(4):E10. https:\/\/doi.org\/10.3171\/foc.1997.2.4.11","journal-title":"Neurosurg Focus"},{"issue":"20","key":"4715_CR48","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1002\/cncr.27460","volume":"118","author":"M Preusser","year":"2012","unstructured":"Preusser M, Spiegl-Kreinecker S, L\u00f6tsch D, W\u00f6hrer A, Schmook M, Dieckmann K, Saringer W, Marosi C, Berger W (2012) Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer 118(20):5038\u20135049. https:\/\/doi.org\/10.1002\/cncr.27460","journal-title":"Cancer"},{"issue":"4","key":"4715_CR49","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/2018.1.FOCUS17754","volume":"44","author":"S Gupta","year":"2018","unstructured":"Gupta S, Bi WL, Dunn IF (2018) Medical management of meningioma in the era of precision medicine. Neurosurg Focus 44(4):E3. https:\/\/doi.org\/10.3171\/2018.1.FOCUS17754","journal-title":"Neurosurg Focus"},{"issue":"2","key":"4715_CR50","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1159\/000477844","volume":"10","author":"WL Read","year":"2017","unstructured":"Read WL, Williams F (2017) Recurrent meningioma of the cervical spine, successfully treated with liposomal doxorubicin. Case Rep Oncol 10(2):656\u2013659. https:\/\/doi.org\/10.1159\/000477844","journal-title":"Case Rep Oncol"},{"issue":"3","key":"4715_CR51","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11060-013-1148-9","volume":"113","author":"S Curic","year":"2013","unstructured":"Curic S, Wu Y, Shan B, Schaaf C, Utpadel D, Lange M, Kuhlen D, Perone MJ, Arzt E, Stalla GK, Renner U (2013) Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas. J Neuro-oncol. 113(3):385\u2013396. https:\/\/doi.org\/10.1007\/s11060-013-1148-9","journal-title":"J Neuro-oncol."},{"issue":"05","key":"4715_CR52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1055\/s-2002-32090","volume":"68","author":"YS Park","year":"2002","unstructured":"Park YS, Lee JH, Bondar J, Harwalkar JA, Safayhi H, Golubic M (2002) Cytotoxic action of acetyl-11-keto-\u03b2-boswellic acid (AKBA) on meningioma cells. Planta Med 68(05):397\u2013401. https:\/\/doi.org\/10.1055\/s-2002-32090","journal-title":"Planta Med"},{"issue":"5","key":"4715_CR53","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3171\/jns.1996.84.5.0733","volume":"84","author":"MC Chamberlain","year":"1996","unstructured":"Chamberlain MC (1996) Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 84(5):733\u2013736. https:\/\/doi.org\/10.3171\/jns.1996.84.5.0733","journal-title":"J Neurosurg"},{"issue":"2","key":"4715_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127\u2013137","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4715_CR55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev-physiol-021113-170406","volume":"76","author":"B Singh","year":"2014","unstructured":"Singh B, Coffey RJ (2014) Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. Annu Rev Physiol 76:275. https:\/\/doi.org\/10.1146\/annurev-physiol-021113-170406","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"4715_CR56","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00401-004-0875-6","volume":"108","author":"U Andersson","year":"2004","unstructured":"Andersson U, Guo D, Malmer B, Bergenheim AT, Br\u00e4nnstr\u00f6m T, Hedman H, Henriksson R (2004) Epidermal growth factor receptor family (EGFR, ErbB2\u20134) in gliomas and meningiomas. Acta Neuropathol 108(2):135\u2013142. https:\/\/doi.org\/10.1007\/s00401-004-0875-6","journal-title":"Acta Neuropathol"},{"issue":"2","key":"4715_CR57","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/0046-8177(94)90270-4","volume":"25","author":"MD Johnson","year":"1994","unstructured":"Johnson MD, Horiba M, Winnier AR, Arteaga CL (1994) The epidermal growth factor receptor is associated with phospholipase C-\u03b31 in meningiomas. Human Pathol 25(2):146\u2013153","journal-title":"Human Pathol"},{"issue":"1","key":"4715_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02478918","volume":"18","author":"G Nagashima","year":"2001","unstructured":"Nagashima G, Asai JI, Suzuki R, Fujimoto T (2001) Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression. Brain Tumor Pathol 18(1):1\u20135. https:\/\/doi.org\/10.1007\/BF02478918","journal-title":"Brain Tumor Pathol"},{"issue":"4","key":"4715_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1054\/jocn.2001.0877","volume":"8","author":"SY Yang","year":"2001","unstructured":"Yang SY, Xu GM (2001) Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci 8(4):49\u201353. https:\/\/doi.org\/10.1054\/jocn.2001.0877","journal-title":"J Clin Neurosci"},{"issue":"5","key":"4715_CR60","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3171\/jns.1996.84.5.0852","volume":"84","author":"T Todo","year":"1996","unstructured":"Todo T, Adams EF, Fahlbusch R, Dingermann T, Werner H (1996) Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg 84(5):852\u2013858. https:\/\/doi.org\/10.3171\/jns.1996.84.5.0852","journal-title":"J Neurosurg"},{"issue":"10","key":"4715_CR61","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/bjc.2012.459","volume":"107","author":"C Pfister","year":"2012","unstructured":"Pfister C, Pfrommer H, Tatagiba MS, Roser F (2012) Vascular endothelial growth factor signals through platelet-derived growth factor receptor \u03b2 in meningiomas in vitro. British J Cancer 107(10):1702\u20131713. https:\/\/doi.org\/10.1038\/bjc.2012.459","journal-title":"British J Cancer"},{"issue":"1","key":"4715_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0670-3","volume":"16","author":"HF Zhao","year":"2017","unstructured":"Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To SS, Li WP (2017) Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer 16(1):1\u20136. https:\/\/doi.org\/10.1186\/s12943-017-0670-3","journal-title":"Mol Cancer"},{"issue":"6","key":"4715_CR63","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0092-8674(00)81519-6","volume":"98","author":"JW Harbour","year":"1999","unstructured":"Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC (1999) Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98(6):859\u2013869. https:\/\/doi.org\/10.1016\/S0092-8674(00)81519-6","journal-title":"Cell"},{"issue":"18","key":"4715_CR64","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1200\/jco.2006.24.18_suppl.1528","volume":"24","author":"WR Shapiro","year":"2006","unstructured":"Shapiro WR, Schmid M, Glantz M, Miller JJ (2006) A randomized phase III\/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 24(18):1528","journal-title":"J Clin Oncol"},{"key":"4715_CR65","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02872","author":"AM Narasimha","year":"2014","unstructured":"Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF (2014) Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. Elife. https:\/\/doi.org\/10.7554\/eLife.02872","journal-title":"Elife"},{"issue":"11\u201312","key":"4715_CR66","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/1947601913478972","volume":"3","author":"SJ Baker","year":"2012","unstructured":"Baker SJ, Reddy EP (2012) CDK4: a key player in the cell cycle, development, and cancer. Gene Cancer. 3(11\u201312):658\u2013669. https:\/\/doi.org\/10.1177\/1947601913478972","journal-title":"Gene Cancer."},{"issue":"11","key":"4715_CR67","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s12094-020-02341-7","volume":"22","author":"A Das","year":"2020","unstructured":"Das A, Alshareef M, Martinez Santos JL, Porto GB, McDonald DG, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D (2020) Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations. Clin Trans Oncol 22(11):2017\u20132025. https:\/\/doi.org\/10.1007\/s12094-020-02341-7","journal-title":"Clin Trans Oncol"},{"issue":"13","key":"4715_CR68","doi-asserted-by":"publisher","first-page":"10671","DOI":"10.18632\/oncotarget.3870","volume":"6","author":"P Domingues","year":"2015","unstructured":"Domingues P, Gonz\u00e1lez-Tablas M, Otero \u00c1, Pascual D, Ruiz L, Miranda D, Sousa P, Gon\u00e7alves JM, Lopes MC, Orfao A, Tabernero MD (2015) Genetic\/molecular alterations of meningiomas and the signaling pathways targeted. Oncotarget 6(13):10671. https:\/\/doi.org\/10.18632\/oncotarget.3870","journal-title":"Oncotarget"},{"key":"4715_CR69","unstructured":"Available online: https:\/\/clinicaltrials.gov Accessed on 30 Aug 2022"},{"issue":"1","key":"4715_CR70","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ygyno.2014.04.044","volume":"134","author":"NR Shah","year":"2014","unstructured":"Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, Sulzmaier FJ, Uryu S, Miller NL, Connolly DC, Schlaepfer DD (2014) Analyses of merlin\/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol 134(1):104\u2013111. https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.044","journal-title":"Gynecol Oncol"},{"key":"4715_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008639","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q (2014) Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3008639","journal-title":"Sci Transl Med"},{"issue":"19","key":"4715_CR72","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1158\/1078-0432.CCR-12-0299","volume":"19","author":"A Wilisch-Neumann","year":"2013","unstructured":"Wilisch-Neumann A, Kliese N, Pachow D, Schneider T, Warnke JP, Braunsdorf WE, B\u00f6hmer FD, Hass P, Pasemann D, Helbing C, Kirches E (2013) The integrin inhibitor cilengitide affects meningioma cell motility and invasioncilengitide in meningiomas. Clin Cancer Res 19(19):5402\u20135412. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0299","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4715_CR73","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","volume":"96","author":"AD Norden","year":"2010","unstructured":"Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, DeAngelis LM (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neuro-oncol. 96(2):211\u2013217. https:\/\/doi.org\/10.1007\/s11060-009-9948-7","journal-title":"J Neuro-oncol."},{"issue":"3","key":"4715_CR74","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","volume":"139","author":"DS Osorio","year":"2018","unstructured":"Osorio DS, Hu J, Mitchell C, Allen JC, Stanek J, Hagiwara M, Karajannis MA (2018) Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J Neuro-oncol 139(3):749\u2013755. https:\/\/doi.org\/10.1007\/s11060-018-2922-5","journal-title":"J Neuro-oncol"},{"issue":"1","key":"4715_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-5-46","volume":"5","author":"AG Wernicke","year":"2010","unstructured":"Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, Hammond EH, Perry A, Andrews DW, Kenyon L (2010) Assessment of epidermal growth factor receptor (EGFR) expression in human meningioma. Radiation Oncol 5(1):1\u20137. https:\/\/doi.org\/10.1186\/1748-717X-5-46","journal-title":"Radiation Oncol"},{"issue":"1","key":"4715_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/cns.12.38","volume":"2","author":"MC Chamberlain","year":"2013","unstructured":"Chamberlain MC (2013) Is there effective systemic therapy for recurrent surgery-and radiation-refractory meningioma? CNS Oncol. 2(1):1\u20135. https:\/\/doi.org\/10.2217\/cns.12.38","journal-title":"CNS Oncol."},{"issue":"12","key":"4715_CR77","first-page":"6391","volume":"35","author":"G Caruso","year":"2015","unstructured":"Caruso G, Elbabaa SK, Gonzalez-Lopez P, Barresi V, Passalacqua M, Caffo M (2015) Innovative therapeutic strategies in the treatment of meningioma. Anticancer Res 35(12):6391\u20136400","journal-title":"Anticancer Res"},{"issue":"9b","key":"4715_CR78","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/j.1582-4934.2009.00783.x","volume":"13","author":"HK Gan","year":"2009","unstructured":"Gan HK, Lappas M, Cao DX, Cvrljevdic A, Scott AM, Johns TG (2009) Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-\u03baB and initiates tumour vascular normalization. J Cell Mol Med 13(9b):3993\u20134001. https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00783.x","journal-title":"J Cell Mol Med"},{"key":"4715_CR79","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","volume":"1","author":"MS Ramakrishnan","year":"2009","unstructured":"Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind A (2009) Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 1:41\u201348","journal-title":"MAbs"},{"issue":"6","key":"4715_CR80","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1215\/15228517-2009-010","volume":"11","author":"PY Wen","year":"2009","unstructured":"Wen PY, Yung WA, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, DeAngelis LM (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American brain tumor consortium study 01\u201308). Neuro Oncol 11(6):853\u2013860. https:\/\/doi.org\/10.1215\/15228517-2009-010","journal-title":"Neuro Oncol"},{"issue":"7","key":"4715_CR81","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/neuonc\/nor056","volume":"13","author":"S Ammoun","year":"2011","unstructured":"Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO (2011) Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol 13(7):759\u2013766. https:\/\/doi.org\/10.1093\/neuonc\/nor056","journal-title":"Neuro Oncol"},{"issue":"1","key":"4715_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-60156-6","volume":"10","author":"JE Sagers","year":"2020","unstructured":"Sagers JE, Beauchamp RL, Zhang Y, Vasilijic S, Wu L, DeSouza P, Seist R, Zhou W, Xu L, Ramesh V, Stankovic KM (2020) Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma. Sci Rep 10(1):1. https:\/\/doi.org\/10.1038\/s41598-020-60156-6","journal-title":"Sci Rep"},{"issue":"1","key":"4715_CR83","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","volume":"109","author":"E Lou","year":"2012","unstructured":"Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE, McSherry F, Norfleet J, Friedman HS (2012) Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series. Journal of Neuro-oncol 109(1):63\u201370. https:\/\/doi.org\/10.1007\/s11060-012-0861-0","journal-title":"Journal of Neuro-oncol"},{"key":"4715_CR84","unstructured":"Available online: https:\/\/go.drugbank.com Accessed on 30 Aug 2022."},{"key":"4715_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2016.12.004","volume":"73","author":"M Tuchen","year":"2017","unstructured":"Tuchen M, Wilisch-Neumann A, Daniel EA, Baldauf L, Pachow D, Scholz J, Angenstein F, Stork O, Kirches E, Mawrin C (2017) Receptor tyrosine kinase inhibition by regorafenib\/sorafenib inhibits growth and invasion of meningioma cells. Euro J Cancer. 73:9\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.004","journal-title":"Euro J Cancer."},{"issue":"1","key":"4715_CR86","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nou148","volume":"17","author":"TJ Kaley","year":"2015","unstructured":"Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A (2015) Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 17(1):116\u2013121. https:\/\/doi.org\/10.1093\/neuonc\/nou148","journal-title":"Neuro Oncol"},{"key":"4715_CR87","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/neuonc\/not247","volume":"16","author":"PY Wen","year":"2014","unstructured":"Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP et al (2014) Phase I\/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American brain tumor consortium trial 04\u201302. Neuro Oncol 16:567\u2013578","journal-title":"Neuro Oncol"},{"issue":"3","key":"4715_CR88","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","volume":"26","author":"T Graillon","year":"2020","unstructured":"Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyri\u00e8re H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH (2020) Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trialeverolimus and octreotide in aggressive meningiomas. Clin Cancer Res 26(3):552\u2013557. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2109","journal-title":"Clin Cancer Res"},{"key":"4715_CR89","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw320","author":"M Weller","year":"2017","unstructured":"Weller M, Roth P, Sahm F, Burghardt I, Schuknecht B, Rushing EJ, Regli L, Lindemann JP, Von Deimling A (2017) Durable control of metastatic AKT1-mutant WHO grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djw320","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4715_CR90","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/biomedicines6030086","volume":"6","author":"F Nigim","year":"2018","unstructured":"Nigim F, Wakimoto H, Kasper EM, Ackermans L, Temel Y (2018) Emerging medical treatments for meningioma in the molecular era. Biomedicines. 6(3):86. https:\/\/doi.org\/10.3390\/biomedicines6030086","journal-title":"Biomedicines."},{"key":"4715_CR91","doi-asserted-by":"publisher","first-page":"104753","DOI":"10.1016\/j.oraloncology.2020.104753","volume":"108","author":"D Day","year":"2020","unstructured":"Day D, Prawira A, Spreafico A, Waldron J, Karithanam R, Giuliani M, Weinreb I, Kim J, Cho J, Hope A, Bayley A (2020) Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Oral Oncol 108:104753. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104753","journal-title":"Oral Oncol"},{"key":"4715_CR92","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab085","author":"C Horbinski","year":"2021","unstructured":"Horbinski C, Xi G, Wang Y, Hashizume R, Gopalakrishnan M, Phillips JJ, Houghton P, James CD, Kalapurakal JA (2021) The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. Neuro-oncol Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdab085","journal-title":"Neuro-oncol Adv"},{"key":"4715_CR93","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2021-0003","author":"I Maggio","year":"2021","unstructured":"Maggio I, Franceschi E, Tosoni A, Nunno VD, Gatto L, Lodi R, Brandes AA (2021) Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncol. https:\/\/doi.org\/10.2217\/cns-2021-0003","journal-title":"CNS Oncol"},{"key":"4715_CR94","unstructured":"Available online: https:\/\/ichgcp.net Accessed on 30 Aug 2022."},{"issue":"36","key":"4715_CR95","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1038\/s41388-018-0328-7","volume":"37","author":"J Boetto","year":"2018","unstructured":"Boetto J, Apra C, Bielle F, Peyre M, Kalamarides M (2018) Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation. Oncogene 37(36):4955\u20134963. https:\/\/doi.org\/10.1038\/s41388-018-0328-7","journal-title":"Oncogene"},{"issue":"10","key":"4715_CR96","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1158\/1055-9965.EPI-08-0406","volume":"17","author":"A Wigertz","year":"2008","unstructured":"Wigertz A, L\u00f6nn S, Hall P, Auvinen A, Christensen HC, Johansen C, Kl\u00e6boe L, Salminen T, Schoemaker MJ, Swerdlow AJ, Tynes T (2008) Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prevent. 17(10):2663\u20132670. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-0406","journal-title":"Cancer Epidemiol Biomarkers Prevent."},{"issue":"8","key":"4715_CR97","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1212\/WNL.25.8.705","volume":"25","author":"BS Schoenberg","year":"1975","unstructured":"Schoenberg BS, Christine BW, Whisnant JP (1975) Nervous system neoplasms and primary malignancies of other sites: the unique association between meningiomas and breast cancer. Neurology 25(8):705. https:\/\/doi.org\/10.1212\/WNL.25.8.705","journal-title":"Neurology"},{"issue":"3","key":"4715_CR98","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF00165650","volume":"29","author":"IE McCutcheon","year":"1996","unstructured":"McCutcheon IE (1996) The biology of meningiomas. J Neuro-oncol. 29(3):207\u2013216. https:\/\/doi.org\/10.1007\/BF00165650","journal-title":"J Neuro-oncol."},{"issue":"1","key":"4715_CR99","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3171\/jns.1997.86.1.0113","volume":"86","author":"DW Hsu","year":"1997","unstructured":"Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86(1):113\u2013120. https:\/\/doi.org\/10.3171\/jns.1997.86.1.0113","journal-title":"J Neurosurg"},{"issue":"4","key":"4715_CR100","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.21873\/anticanres.13301","volume":"39","author":"JH Check","year":"2019","unstructured":"Check JH, Check D, Poretta T (2019) Mifepristone extends both length and quality of life in a patient with advanced non-small cell lung cancer that has progressed despite chemotherapy and a check-point inhibitor. Anticancer Res 39(4):1923\u20131926. https:\/\/doi.org\/10.21873\/anticanres.13301","journal-title":"Anticancer Res"},{"issue":"2","key":"4715_CR101","first-page":"1","volume":"3","author":"DL Check","year":"2020","unstructured":"Check DL, Check JH, Poretta T, Aikins J, Wilson CJ (2020) Prolonged high-quality life in patients with non-small cell lung cancer treated with mifepristone who advanced despite osimertinib. Cancer Sci Res 3(2):1\u20135","journal-title":"Cancer Sci Res"},{"issue":"12","key":"4715_CR102","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.21873\/anticanres.11251","volume":"36","author":"JH Check","year":"2016","unstructured":"Check JH, Check D, Wilson C, Lofberg P (2016) Long-term high-quality survival with single-agent mifepristone treatment despite advanced cancer. Anticancer Res 36(12):6511\u20136513","journal-title":"Anticancer Res"},{"issue":"12","key":"4715_CR103","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.21873\/anticanres.14724","volume":"40","author":"JH Check","year":"2020","unstructured":"Check JH, Check D, Srivastava MD, Poretta T, Aikins JK (2020) Treatment with mifepristone allows a patient with end-stage pancreatic cancer in hospice on a morphine drip to restore a decent quality of life. Anticancer Res 40(12):6997\u20137001. https:\/\/doi.org\/10.21873\/anticanres.14724","journal-title":"Anticancer Res"},{"issue":"6","key":"4715_CR104","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.arcmed.2016.10.002","volume":"47","author":"L Germ\u00e1n-Castel\u00e1n","year":"2016","unstructured":"Germ\u00e1n-Castel\u00e1n L, Manjarrez-Marmolejo J, Gonz\u00e1lez-Arenas A, Camacho-Arroyo I (2016) Intracellular progesterone receptor mediates the increase in glioblastoma growth induced by progesterone in the rat brain. Archiv Med Res. 47(6):419\u2013426. https:\/\/doi.org\/10.1016\/j.arcmed.2016.10.002","journal-title":"Archiv Med Res."},{"issue":"2","key":"4715_CR105","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12020-007-9023-0","volume":"32","author":"G Gonz\u00e1lez-Ag\u00fcero","year":"2007","unstructured":"Gonz\u00e1lez-Ag\u00fcero G, Guti\u00e9rrez AA, Gonz\u00e1lez-Espinosa D, Solano JD, Morales R, Gonz\u00e1lez-Arenas A, Cabrera-Munoz E, Camacho-Arroyo I (2007) Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines. Endocrine 32(2):129\u2013135. https:\/\/doi.org\/10.1007\/s12020-007-9023-0","journal-title":"Endocrine"},{"key":"4715_CR106","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.steroids.2015.11.008","volume":"105","author":"AG Pi\u00f1a-Medina","year":"2016","unstructured":"Pi\u00f1a-Medina AG, Hansberg-Pastor V, Gonz\u00e1lez-Arenas A, Cerb\u00f3n M, Camacho-Arroyo I (2016) Progesterone promotes cell migration, invasion and cofilin activation in human astrocytoma cells. Steroids 105:19\u201325. https:\/\/doi.org\/10.1016\/j.steroids.2015.11.008","journal-title":"Steroids"},{"issue":"3","key":"4715_CR107","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bjc.6690705","volume":"81","author":"MP Pereda","year":"1999","unstructured":"Pereda MP, Hopfner U, Pagotto U, Renner U, Uhl E, Arzt E, Missale C, Stalla GK (1999) Retinoic acid stimulates meningioma cell adhesion to the extracellular matrix and inhibits invasion. Br J Cancer 81(3):381\u2013386. https:\/\/doi.org\/10.1038\/sj.bjc.6690705","journal-title":"Br J Cancer"},{"issue":"1","key":"4715_CR108","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF00182088","volume":"8","author":"SM Grunberg","year":"1990","unstructured":"Grunberg SM, Weiss MH (1990) Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neuro-oncol. 8(1):61\u201365. https:\/\/doi.org\/10.1007\/BF00182088","journal-title":"J Neuro-oncol."},{"issue":"6","key":"4715_CR109","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/jnnp.55.6.486","volume":"55","author":"SW Lamberts","year":"1992","unstructured":"Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW, De Jong H (1992) Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55(6):486\u2013490. https:\/\/doi.org\/10.1136\/jnnp.55.6.486","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"4715_CR110","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/CEJ.0000000000000133","volume":"25","author":"J Ji","year":"2016","unstructured":"Ji J, Sundquist J, Sundquist K (2016) Association of tamoxifen with meningioma: a population-based study in Sweden. Euro J Cancer Prevent 25(1):29. https:\/\/doi.org\/10.1097\/CEJ.0000000000000133","journal-title":"Euro J Cancer Prevent"},{"issue":"2","key":"4715_CR111","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3171\/2015.1.JNS142260","volume":"124","author":"R Rammo","year":"2016","unstructured":"Rammo R, Rock A, Transou A, Raghunathan A, Rock J (2016) Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease. J Neurosurg 124(2):496\u2013500. https:\/\/doi.org\/10.3171\/2015.1.JNS142260","journal-title":"J Neurosurg"},{"key":"4715_CR112","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","volume":"84","author":"AD Norden","year":"2015","unstructured":"Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET et al (2015) Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 84:280\u2013286","journal-title":"Neurology"},{"issue":"4","key":"4715_CR113","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2147\/nano.2006.1.4.385","volume":"1","author":"F Roelfsema","year":"2006","unstructured":"Roelfsema F, Biermasz NR, Pereira AM, Romijn JM (2006) Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int J Nanomed 1(4):385. https:\/\/doi.org\/10.2147\/nano.2006.1.4.385","journal-title":"Int J Nanomed"},{"issue":"4","key":"4715_CR114","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/0008-5472.CAN-04-0786","volume":"65","author":"VK Puduvalli","year":"2005","unstructured":"Puduvalli VK, Li JT, Chen L, McCutcheon IE (2005) Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res 65(4):1547\u20131553. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0786","journal-title":"Cancer Res"},{"key":"4715_CR115","doi-asserted-by":"publisher","first-page":"e1512943","DOI":"10.1080\/2162402X.2018.1512943","volume":"8","author":"DT Proctor","year":"2019","unstructured":"Proctor DT, Patel Z, Lama S, Resch L, Van Marle G, Sutherland GR (2019) Identification of PD-L2, B7\u2013H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. Oncoimmunology 8:e1512943. https:\/\/doi.org\/10.1080\/2162402X.2018.1512943","journal-title":"Oncoimmunology"},{"issue":"5","key":"4715_CR116","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1158\/2326-6066.CIR-13-0029","volume":"1","author":"GS Baia","year":"2013","unstructured":"Baia GS, Caballero OL, Ho JS, Zhao Q, Cohen T, Binder ZA, Salmasi V, Gallia GL, Quinones-Hinojosa A, Olivi A, Brem H (2013) NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approachesNY-ESO-1 expression in meningioma. Cancer Immunol Res 1(5):296\u2013302. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0029","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"4715_CR117","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","volume":"130","author":"SJ Han","year":"2016","unstructured":"Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA (2016) Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neuro-oncol. 130(3):543\u2013552. https:\/\/doi.org\/10.1007\/s11060-016-2256-0","journal-title":"J Neuro-oncol."},{"issue":"2","key":"4715_CR118","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00006123-199702000-00007","volume":"40","author":"SE Kaba","year":"1997","unstructured":"Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Victor L, Yung WA (1997) The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40(2):271\u2013275","journal-title":"Neurosurgery"},{"key":"4715_CR119","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130688","author":"AJ Giles","year":"2019","unstructured":"Giles AJ, Hao S, Padget M, Song H, Zhang W, Lynes J, Sanchez V, Liu Y, Jung J, Cao X, Fujii R (2019) Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.130688","journal-title":"JCI Insight"},{"issue":"1","key":"4715_CR120","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ijc.27658","volume":"132","author":"F Zhi","year":"2013","unstructured":"Zhi F, Zhou G, Wang S, Shi Y, Peng Y, Shao N, Guan W, Qu H, Zhang Y, Wang Q, Yang C (2013) A microRNA expression signature predicts meningioma recurrence. Int J Cancer 132(1):128\u2013136. https:\/\/doi.org\/10.1002\/ijc.27658","journal-title":"Int J Cancer"},{"issue":"1","key":"4715_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3198-4","volume":"17","author":"AB Dalan","year":"2017","unstructured":"Dalan AB, Gulluoglu S, Tuysuz EC, Kuskucu A, Yaltirik CK, Ozturk O, Ture U, Bayrak OF (2017) Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c. BMC Cancer 17(1):1\u20139. https:\/\/doi.org\/10.1186\/s12885-017-3198-4","journal-title":"BMC Cancer"},{"issue":"39","key":"4715_CR122","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/onc.2012.468","volume":"32","author":"N Kliese","year":"2013","unstructured":"Kliese N, Gobrecht P, Pachow D, Andrae N, Wilisch-Neumann A, Kirches E, Riek-Burchardt M, Angenstein F, Reifenberger G, Riemenschneider MJ, Meese E (2013) miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 32(39):4712\u20134720. https:\/\/doi.org\/10.1038\/onc.2012.468","journal-title":"Oncogene"},{"issue":"2","key":"4715_CR123","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11060-012-0951-z","volume":"110","author":"L Shi","year":"2012","unstructured":"Shi L, Jiang D, Sun G, Wan Y, Zhang S, Zeng Y, Pan T, Wang Z (2012) miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neuro-oncol. 110(2):155\u2013162. https:\/\/doi.org\/10.1007\/s11060-012-0951-z","journal-title":"J Neuro-oncol."},{"issue":"9","key":"4715_CR124","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/neuonc\/nor072","volume":"13","author":"ML Bush","year":"2011","unstructured":"Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR (2011) AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol 13(9):983\u2013999. https:\/\/doi.org\/10.1093\/neuonc\/nor072","journal-title":"Neuro Oncol"},{"issue":"10","key":"4715_CR125","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1158\/0008-5472.CAN-05-1628","volume":"66","author":"MA Gerber","year":"2006","unstructured":"Gerber MA, Bahr SM, Gutmann DH (2006) Protein 4.1 B\/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH2-kinase signaling. Cancer Res 66(10):5295\u20135303. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1628","journal-title":"Cancer Res"},{"issue":"2","key":"4715_CR126","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/ijms22020690","volume":"22","author":"S Bachir","year":"2021","unstructured":"Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN, Zuccarello M, Schorry E, Sengupta S (2021) Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. Int J Mol Sci 22(2):690. https:\/\/doi.org\/10.3390\/ijms22020690","journal-title":"Int J Mol Sci"},{"issue":"101","key":"4715_CR127","first-page":"301","volume":"18","author":"X Zhang","year":"2014","unstructured":"Zhang X, Jia H, Lu Y, Dong C, Hou J, Wang Z, Wang F, Zhong H, Wang L, Wang K (2014) Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes. Discov Med 18(101):301","journal-title":"Discov Med"},{"issue":"3","key":"4715_CR128","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-014-1678-9","volume":"121","author":"Y Liu","year":"2015","unstructured":"Liu Y, Shi J, Chen M, Cao YF, Liu YW, Pan J, Qi ST (2015) Periostin: a novel prognostic predictor for meningiomas. J Neuro-oncol. 121(3):505\u2013512. https:\/\/doi.org\/10.1007\/s11060-014-1678-9","journal-title":"J Neuro-oncol."},{"key":"4715_CR129","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018644","author":"N Liu","year":"2020","unstructured":"Liu N, Song SY, Jiang JB, Wang TJ, Yan CX (2020) The prognostic role of Ki-67\/MIB-1 in meningioma: A systematic review with meta-analysis. Medicine. https:\/\/doi.org\/10.1097\/MD.0000000000018644","journal-title":"Medicine"},{"issue":"11","key":"4715_CR130","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.3390\/cancers12113437","volume":"12","author":"MR Subeha","year":"2020","unstructured":"Subeha MR, Telleria CM (2020) The anti-cancer properties of the hiv protease inhibitor nelfinavir. Cancers 12(11):3437. https:\/\/doi.org\/10.3390\/cancers12113437","journal-title":"Cancers"},{"issue":"3","key":"4715_CR131","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11060-010-0281-y","volume":"101","author":"MD Johnson","year":"2011","unstructured":"Johnson MD, O\u2019Connell M, Pilcher W (2011) Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism. J Neuro-oncol 101(3):441\u2013448. https:\/\/doi.org\/10.1007\/s11060-010-0281-y","journal-title":"J Neuro-oncol"},{"issue":"1","key":"4715_CR132","doi-asserted-by":"publisher","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","volume":"21","author":"PK Brastianos","year":"2019","unstructured":"Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A (2019) Advances in multidisciplinary therapy for meningiomas. Neuro Oncol 21(1):i18\u2013i31. https:\/\/doi.org\/10.1093\/neuonc\/noy136","journal-title":"Neuro Oncol"},{"issue":"3","key":"4715_CR133","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/00006123-200003000-00032","volume":"46","author":"RL Jensen","year":"2000","unstructured":"Jensen RL, Petr M, Wurster RD (2000) Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation. Neurosurgery 46(3):692\u2013703","journal-title":"Neurosurgery"},{"issue":"3","key":"4715_CR134","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11060-010-0351-1","volume":"102","author":"S Gehring","year":"2011","unstructured":"Gehring S, Tapia-P\u00e9rez JH, Kirches E, Firsching R, Keilhoff G, Schneider T, Mawrin C (2011) Cytotoxic effects of statins and thiazolidinediones on meningioma cells. J Neuro-Oncol. 102(3):383\u2013393. https:\/\/doi.org\/10.1007\/s11060-010-0351-1","journal-title":"J Neuro-Oncol."},{"key":"4715_CR135","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5286358","author":"DM Abarca-Merlin","year":"2019","unstructured":"Abarca-Merlin DM, Maldonado-Bernal C, Alvarez-Arellano L (2019) Toll-like receptors as therapeutic targets in central nervous system tumors. BioMed Res Int. https:\/\/doi.org\/10.1155\/2019\/5286358","journal-title":"BioMed Res Int"},{"issue":"4","key":"4715_CR136","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/neuonc\/now235","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA (2017) Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol 19(4):535\u2013545. https:\/\/doi.org\/10.1093\/neuonc\/now235","journal-title":"Neuro Oncol"},{"issue":"1","key":"4715_CR137","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3892\/ijo.29.1.25","volume":"29","author":"S Kondraganti","year":"2006","unstructured":"Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC (2006) Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol 29(1):25\u201332. https:\/\/doi.org\/10.3892\/ijo.29.1.25","journal-title":"Int J Oncol"},{"key":"4715_CR138","doi-asserted-by":"publisher","DOI":"10.3171\/foc.1997.2.4.12","author":"UM Schrell","year":"1997","unstructured":"Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. Neurosurg Focus. https:\/\/doi.org\/10.3171\/foc.1997.2.4.12","journal-title":"Neurosurg Focus"},{"key":"4715_CR139","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1023\/A:1026770624783","volume":"49","author":"HB Newton","year":"2000","unstructured":"Newton HB, Slivka MA, Stevens C (2000) Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neuro-oncol. 49:165\u2013170. https:\/\/doi.org\/10.1023\/A:1026770624783","journal-title":"J Neuro-oncol."},{"issue":"2","key":"4715_CR140","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3171\/jns.2002.97.2.0341","volume":"97","author":"WP Mason","year":"2002","unstructured":"Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningiomas. J Neurosurg 97(2):341\u2013346. https:\/\/doi.org\/10.3171\/jns.2002.97.2.0341","journal-title":"J Neurosurg"},{"issue":"2","key":"4715_CR141","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1054\/jocn.2001.1019","volume":"9","author":"MA Rosenthal","year":"2002","unstructured":"Rosenthal MA, Ashley DL, Cher L (2002) Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci 9(2):156\u2013158. https:\/\/doi.org\/10.1054\/jocn.2001.1019","journal-title":"J Clin Neurosci"},{"key":"4715_CR142","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1023\/B:NEON.0000021827.85754.8e","volume":"67","author":"D Loven","year":"2004","unstructured":"Loven D, Hardoff R, Bar Sever Z, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A (2004) Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neuro-oncol 67:221\u2013226. https:\/\/doi.org\/10.1023\/B:NEON.0000021827.85754.8e","journal-title":"J Neuro-oncol"},{"issue":"5","key":"4715_CR143","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/02688690400012392","volume":"18","author":"HB Newton","year":"2004","unstructured":"Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18(5):495\u2013499. https:\/\/doi.org\/10.1080\/02688690400012392","journal-title":"Br J Neurosurg"},{"key":"4715_CR144","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-004-2337-3","volume":"74","author":"BM Hahn","year":"2005","unstructured":"Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG (2005) Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neuro-oncol. 74:157\u2013165. https:\/\/doi.org\/10.1007\/s11060-004-2337-3","journal-title":"J Neuro-oncol."},{"issue":"03","key":"4715_CR145","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1055\/s-2006-949518","volume":"16","author":"GJ Weston","year":"2006","unstructured":"Weston GJ, Martin AJ, Mufti GJ, Strong AJ, Gleeson MJ (2006) Hydroxyurea treatment of meningiomas: a pilot study. Skull Base. 16(03):157\u2013160. https:\/\/doi.org\/10.1055\/s-2006-949518","journal-title":"Skull Base."},{"key":"4715_CR146","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.wneu.2015.09.060","volume":"86","author":"M Karsy","year":"2016","unstructured":"Karsy M, Hoang N, Barth T, Burt L, Dunson W, Gillespie DL, Jensen RL (2016) Combined hydroxyurea and verapamil in the clinical treatment of refractory meningioma: human and orthotopic xenograft studies. World Neurosurg 86:210\u2013219. https:\/\/doi.org\/10.1016\/j.wneu.2015.09.060","journal-title":"World Neurosurg"},{"issue":"6","key":"4715_CR147","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3171\/jns.1991.74.6.0861","volume":"74","author":"SM Grunberg","year":"1991","unstructured":"Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL (1991) Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74(6):861\u2013866. https:\/\/doi.org\/10.3171\/jns.1991.74.6.0861","journal-title":"J Neurosurg"},{"issue":"8","key":"4715_CR148","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/07357900601062339","volume":"24","author":"SM Grunberg","year":"2006","unstructured":"Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Investig 24(8):727\u2013733. https:\/\/doi.org\/10.1080\/07357900601062339","journal-title":"Cancer Investig"},{"issue":"6","key":"4715_CR149","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1128\/MCB.01392-08","volume":"29","author":"SS Houshmandi","year":"2009","unstructured":"Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH (2009) The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2-and Src-dependent manner. Mol Cell Biol 29(6):1472\u20131486. https:\/\/doi.org\/10.1128\/MCB.01392-08","journal-title":"Mol Cell Biol"},{"key":"4715_CR150","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","volume":"117","author":"JJ Raizer","year":"2014","unstructured":"Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I, Rice L, McCarthy K, Johnston SK, Mrugala MM, Chamberlain M (2014) A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neuro-oncol. 117:93\u2013101. https:\/\/doi.org\/10.1007\/s11060-014-1358-9","journal-title":"J Neuro-oncol."},{"issue":"2","key":"4715_CR151","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nec.2015.11.002","volume":"27","author":"M Karsy","year":"2016","unstructured":"Karsy M, Guan J, Cohen A, Colman H, Jensen RL (2016) Medical management of meningiomas: current status, failed treatments, and promising horizons. Neurosurg Clin 27(2):249\u2013260. https:\/\/doi.org\/10.1016\/j.nec.2015.11.002","journal-title":"Neurosurg Clin"},{"issue":"3","key":"4715_CR152","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/1078155218799850","volume":"25","author":"CA Dasanu","year":"2019","unstructured":"Dasanu CA, Samara Y, Codreanu I, Limonadi FM, Hamid O, Alvarez-Argote J (2019) Systemic therapy for relapsed\/refractory meningioma: Is there potential for antiangiogenic agents? J Oncol Pharm Pract 25(3):638\u2013647. https:\/\/doi.org\/10.1177\/1078155218799850","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"4715_CR153","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379(1):54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002","journal-title":"N Engl J Med"},{"issue":"1","key":"4715_CR154","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4132\/jptm.2014.10.13","volume":"49","author":"S Yun","year":"2015","unstructured":"Yun S, Koh JM, Lee KS, Seo AN, Nam KH, Choe G (2015) Expression of c-MET in invasive meningioma. J Pathol Transl Med. 49(1):44\u201351. https:\/\/doi.org\/10.4132\/jptm.2014.10.13","journal-title":"J Pathol Transl Med."},{"issue":"2","key":"4715_CR155","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","volume":"14","author":"M Preusser","year":"2018","unstructured":"Preusser M, Brastianos PK, Mawrin C (2018) Advances in meningioma genetics: novel therapeutic opportunities. Nat Rev Neurol 14(2):106\u2013115. https:\/\/doi.org\/10.1038\/nrneurol.2017.168","journal-title":"Nat Rev Neurol"},{"key":"4715_CR156","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00428-005-1264-9","volume":"446","author":"X Dolcet","year":"2005","unstructured":"Dolcet X, Llobet D, Pallares J, Matias-Guiu X (2005) NF-kB in development and progression of human cancer. Virchows Arch 446:475\u2013482. https:\/\/doi.org\/10.1007\/s00428-005-1264-9","journal-title":"Virchows Arch"},{"key":"4715_CR157","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3507","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, Cavalcante L, Bastos BR, Powell SF, Ma WW, Sahebjam S, Harvey D, De Souza AL, Dhawan MS, Safran H, Giles FJ (2020) Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3\u03b2) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.3507","journal-title":"J Clin Oncol"},{"key":"4715_CR158","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2072","author":"BJ Theeler","year":"2021","unstructured":"Theeler BJ, Jung J, Burton E, Leeper H, Wu J, Zaghloul K, Ray-Chaudhury A, Quezado M, Raffeld M, Yuan Y, Aldape KD (2021) First-in-human dose escalation and food effect study of oral ONC206 in adults with recurrent primary CNS neoplasms. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS2072","journal-title":"J Clin Oncol"},{"issue":"7","key":"4715_CR159","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.18632\/oncotarget.3082","volume":"6","author":"Z Du","year":"2015","unstructured":"Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray MA, Viramontes O, Machaidze R, Brastianos PK, Reardon DA, Dunn IF (2015) Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 6(7):4704. https:\/\/doi.org\/10.18632\/oncotarget.3082","journal-title":"Oncotarget"},{"issue":"8","key":"4715_CR160","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","volume":"55","author":"D Wild","year":"2014","unstructured":"Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Rivier JE, Reubi JC, Maecke HR, Weber WA (2014) Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nuclear Med. 55(8):1248\u20131252. https:\/\/doi.org\/10.2967\/jnumed.114.138834","journal-title":"J Nuclear Med."},{"key":"4715_CR161","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/IJN.S37859","volume":"28","author":"G Zhao","year":"2012","unstructured":"Zhao G, Rodriguez BL (2012) Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int J Nanomed 28:61\u201371","journal-title":"Int J Nanomed"},{"issue":"3","key":"4715_CR162","first-page":"878","volume":"8","author":"IF Tannock","year":"2002","unstructured":"Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ (2002) Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8(3):878\u2013884","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4715_CR163","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.3390\/cancers3032888","volume":"3","author":"SA Mousa","year":"2011","unstructured":"Mousa SA, Bharali DJ (2011) Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications. Cancers 3(3):2888\u20132903. https:\/\/doi.org\/10.3390\/cancers3032888","journal-title":"Cancers"},{"issue":"4","key":"4715_CR164","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","volume":"11","author":"R Krishna","year":"2000","unstructured":"Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Euro J Pharm Sci 11(4):265\u2013283. https:\/\/doi.org\/10.1016\/S0928-0987(00)00114-7","journal-title":"Euro J Pharm Sci"},{"issue":"15","key":"4715_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399499001099X","volume":"1","author":"R Brown","year":"1999","unstructured":"Brown R, Links M (1999) Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Exp Rev Mol Med 1(15):1\u201321. https:\/\/doi.org\/10.1017\/S1462399499001099X","journal-title":"Exp Rev Mol Med"},{"issue":"1","key":"4715_CR166","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1146\/annurev.ge.29.120195.003135","volume":"29","author":"MM Gottesman","year":"1995","unstructured":"Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I (1995) Genetic analysis of the multidrug transporter. Ann Rev Gene 29(1):607\u2013649","journal-title":"Ann Rev Gene"},{"issue":"9","key":"4715_CR167","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7(9):771\u2013782. https:\/\/doi.org\/10.1038\/nrd2614","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4715_CR168","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11010-020-03703-z","volume":"467","author":"AS Jadli","year":"2020","unstructured":"Jadli AS, Ballasy N, Edalat P, Patel VB (2020) Inside (sight) of tiny communicator: exosome biogenesis, secretion, and uptake. Mol Cell Biochem 467(1):77\u201394. https:\/\/doi.org\/10.1007\/s11010-020-03703-z","journal-title":"Mol Cell Biochem"},{"key":"4715_CR169","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jconrel.2015.06.029","volume":"219","author":"L Milane","year":"2015","unstructured":"Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM (2015) Exosome mediated communication within the tumor microenvironment. J Control Release 219:278\u2013294. https:\/\/doi.org\/10.1016\/j.jconrel.2015.06.029","journal-title":"J Control Release"},{"issue":"7467","key":"4715_CR170","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, De Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501(7467):346\u2013354. https:\/\/doi.org\/10.1038\/nature12626","journal-title":"Nature"},{"issue":"23","key":"4715_CR171","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1158\/0008-5472.CAN-17-0994","volume":"77","author":"CF Ruivo","year":"2017","unstructured":"Ruivo CF, Adem B, Silva M, Melo SA (2017) The biology of cancer exosomes: insights and new perspectivesbiology of cancer exosomes. Cancer Res 77(23):6480\u20136488. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0994","journal-title":"Cancer Res"},{"issue":"4","key":"4715_CR172","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ceb.2009.03.007","volume":"21","author":"M Simons","year":"2009","unstructured":"Simons M, Raposo G (2009) Exosomes\u2013vesicular carriers for intercellular communication. Curr Opin Cell Biol 21(4):575\u2013581. https:\/\/doi.org\/10.1016\/j.ceb.2009.03.007","journal-title":"Curr Opin Cell Biol"},{"issue":"9","key":"4715_CR173","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.molmed.2015.07.004","volume":"21","author":"Y Fujita","year":"2015","unstructured":"Fujita Y, Kosaka N, Araya J, Kuwano K, Ochiya T (2015) Extracellular vesicles in lung microenvironment and pathogenesis. Trends Mol Med 21(9):533\u2013542. https:\/\/doi.org\/10.1016\/j.molmed.2015.07.004","journal-title":"Trends Mol Med"},{"issue":"18","key":"4715_CR174","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1089\/ars.2019.7935","volume":"34","author":"Z Ma","year":"2021","unstructured":"Ma Z, Wang LZ, Cheng JT, Lam WS, Ma X, Xiang X, Wong AL, Goh BC, Gong Q, Sethi G, Wang L (2021) Targeting hypoxia-inducible factor-1-mediated metastasis for cancer therapy. Antioxid Redox Signal 34(18):1484\u20131497. https:\/\/doi.org\/10.1089\/ars.2019.7935","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"4715_CR175","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2174\/1570161115666170713094319","volume":"15","author":"MK Shanmugam","year":"2017","unstructured":"Shanmugam MK, Warrier S, Kumar AP, Sethi G, Arfuso F (2017) Potential role of natural compounds as anti-angiogenic agents in cancer. Curr Vascular Pharmacol 15(6):503\u2013519. https:\/\/doi.org\/10.2174\/1570161115666170713094319","journal-title":"Curr Vascular Pharmacol"},{"issue":"5","key":"4715_CR176","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1007\/s13277-013-1561-x","volume":"35","author":"J Ye","year":"2014","unstructured":"Ye J, Wu D, Wu P, Chen Z, Huang J (2014) The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumor Biol. 35(5):3945\u20133951. https:\/\/doi.org\/10.1007\/s13277-013-1561-x","journal-title":"Tumor Biol."},{"issue":"1","key":"4715_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"MZ Jin","year":"2020","unstructured":"Jin MZ, Jin WL (2020) The updated landscape of tumor microenvironment and drug repurposing. Sig Transduct Targeted Ther 5(1):1\u20136. https:\/\/doi.org\/10.1038\/s41392-020-00280-x","journal-title":"Sig Transduct Targeted Ther"},{"issue":"8","key":"4715_CR178","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/cancers13081882","volume":"13","author":"A Datta","year":"2021","unstructured":"Datta A, Deng S, Gopal V, Yap KC, Halim CE, Lye ML, Ong MS, Tan TZ, Sethi G, Hooi SC, Kumar AP (2021) Cytoskeletal dynamics in epithelial-mesenchymal transition: insights into therapeutic targets for cancer metastasis. Cancers 13(8):1882. https:\/\/doi.org\/10.3390\/cancers13081882","journal-title":"Cancers"},{"issue":"10","key":"4715_CR179","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/cells8101178","volume":"8","author":"JT Cheng","year":"2019","unstructured":"Cheng JT, Wang L, Wang H, Tang FR, Cai WQ, Sethi G, Xin HW, Ma Z (2019) Insights into biological role of LncRNAs in epithelial-mesenchymal transition. Cells 8(10):1178. https:\/\/doi.org\/10.3390\/cells8101178","journal-title":"Cells"},{"issue":"1","key":"4715_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17622-5","volume":"7","author":"LA Moraes","year":"2017","unstructured":"Moraes LA, Kar S, Foo SL, Gu T, Toh YQ, Ampomah PB, Sachaphibulkij K, Yap G, Zharkova O, Lukman HM, Fairhurst AM (2017) Annexin-A1 enhances breast cancer growth and migration by promoting alternative macrophage polarization in the tumour microenvironment. Sci Rep 7(1):1\u20132. https:\/\/doi.org\/10.1038\/s41598-017-17622-5","journal-title":"Sci Rep"},{"issue":"3","key":"4715_CR181","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.ymthe.2020.11.024","volume":"29","author":"Y Yang","year":"2021","unstructured":"Yang Y, Guo Z, Chen W, Wang X, Cao M, Han X, Zhang K, Teng B, Cao J, Wu W, Cao P (2021) M2 macrophage-derived exosomes promote angiogenesis and growth of pancreatic ductal adenocarcinoma by targeting E2F2. Mol Ther 29(3):1226\u20131238. https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.024","journal-title":"Mol Ther"},{"issue":"9","key":"4715_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-02926-8","volume":"11","author":"F Dong","year":"2020","unstructured":"Dong F, Ruan S, Wang J, Xia Y, Le K, Xiao X, Hu T, Wang Q (2020) M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2. Cell Death Dis 11(9):1\u20134. https:\/\/doi.org\/10.1038\/s41419-020-02926-8","journal-title":"Cell Death Dis"},{"key":"4715_CR183","doi-asserted-by":"publisher","first-page":"153574","DOI":"10.1016\/j.phymed.2021.153574","volume":"87","author":"YY Jung","year":"2021","unstructured":"Jung YY, Um JY, Nasif O, Alharbi SA, Sethi G, Ahn KS (2021) Blockage of the JAK\/STAT3 signaling pathway in multiple myeloma by leelamine. Phytomedicine 87:153574. https:\/\/doi.org\/10.1016\/j.phymed.2021.153574","journal-title":"Phytomedicine"},{"key":"4715_CR184","doi-asserted-by":"publisher","first-page":"188574","DOI":"10.1016\/j.bbcan.2021.188574","volume":"1876","author":"CD Mohan","year":"2021","unstructured":"Mohan CD, Rangappa S, Nayak SC, Sethi G, Rangappa KS (2021) Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 1876:188574. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188574","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"4715_CR185","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/med.21761","volume":"41","author":"M Garg","year":"2021","unstructured":"Garg M, Shanmugam MK, Bhardwaj V, Goel A, Gupta R, Sharma A, Baligar P, Kumar AP, Goh BC, Wang L, Sethi G (2021) The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. Med Res Rev 41(3):1291\u20131336. https:\/\/doi.org\/10.1002\/med.21761","journal-title":"Med Res Rev"},{"key":"4715_CR186","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jare.2021.03.008","volume":"35","author":"YY Jung","year":"2022","unstructured":"Jung YY, Ha IJ, Um JY, Sethi G, Ahn KS (2022) Fangchinoline diminishes STAT3 activation by stimulating oxidative stress and targeting SHP-1 protein in multiple myeloma model. J Adv Res 35:245\u2013257. https:\/\/doi.org\/10.1016\/j.jare.2021.03.008","journal-title":"J Adv Res"},{"key":"4715_CR187","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jare.2020.07.004","volume":"26","author":"JH Lee","year":"2020","unstructured":"Lee JH, Mohan CD, Deivasigamani A, Jung YY, Rangappa S, Basappa S, Chinnathambi A, Alahmadi TA, Alharbi SA, Garg M, Lin ZX (2020) Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma. J Adv Res 26:83\u201394. https:\/\/doi.org\/10.1016\/j.jare.2020.07.004","journal-title":"J Adv Res"},{"issue":"4","key":"4715_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03664-1","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, Zhang J, Zhang Z, Gao Z, Qi Y, Qiu W, Pan Z, Guo Q, Li B, Zhao S, Guo X (2021) Hypoxic glioma-derived exosomes promote M2-like macrophage polarization by enhancing autophagy induction. Cell Death Dis 12(4):1\u20136. https:\/\/doi.org\/10.1038\/s41419-021-03664-1","journal-title":"Cell Death Dis"},{"issue":"16","key":"4715_CR189","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.3390\/ijms20163982","volume":"20","author":"KR Pace","year":"2019","unstructured":"Pace KR, Dutt R, Galileo DS (2019) Exosomal L1CAM stimulates glioblastoma cell motility, proliferation, and invasiveness. Int J Mol Sci 20(16):3982. https:\/\/doi.org\/10.3390\/ijms20163982","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4715_CR190","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.gendis.2019.10.007","volume":"7","author":"AN Lane","year":"2020","unstructured":"Lane AN, Higashi RM, Fan TW (2020) Metabolic reprogramming in tumors: contributions of the tumor microenvironment. Gene Dis 7(2):185\u2013198. https:\/\/doi.org\/10.1016\/j.gendis.2019.10.007","journal-title":"Gene Dis"},{"issue":"1","key":"4715_CR191","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10555-019-09796-3","volume":"38","author":"K Ji","year":"2019","unstructured":"Ji K, Mayernik L, Moin K, Sloane BF (2019) Acidosis and proteolysis in the tumor microenvironment. Cancer Metastasis Rev 38(1):103\u2013112. https:\/\/doi.org\/10.1007\/s10555-019-09796-3","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"4715_CR192","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"03","key":"4715_CR193","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1055\/s-0039-1700321","volume":"5","author":"AR Bhat","year":"2014","unstructured":"Bhat AR, Wani MA, Kirmani AR, Ramzan AU (2014) Histological-subtypes and anatomical location correlated in meningeal brain tumors (meningiomas). J Neurosci Rural Pract 5(03):244\u2013249. https:\/\/doi.org\/10.1055\/s-0039-1700321","journal-title":"J Neurosci Rural Pract"},{"key":"4715_CR194","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-022-04126-0","volume":"8","author":"A Abdelrahman","year":"2022","unstructured":"Abdelrahman A, Negroni C, Sahm F, Adams CL, Urbanic-Purkart T, Khalil M, Vergura R, Morelli C, Hanemann CO (2022) miR-497 and 219 in blood aid meningioma classification. J Neuro-Oncol 8:1\u20131. https:\/\/doi.org\/10.1007\/s11060-022-04126-0","journal-title":"J Neuro-Oncol"},{"key":"4715_CR195","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8326591","author":"XH Fu","year":"2022","unstructured":"Fu XH, Li JP, Li XY, Tan Y, Zhao M, Zhang SF, Wu XD, Xu JG (2022) M2-macrophage-derived exosomes promote meningioma progression through TGF-\u03b2 signaling pathway. J Immunol Res. https:\/\/doi.org\/10.1155\/2022\/8326591","journal-title":"J Immunol Res"},{"issue":"2","key":"4715_CR196","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3390\/ijms22020560","volume":"22","author":"AA Sofela","year":"2021","unstructured":"Sofela AA, Hilton DA, Ammoun S, Baiz D, Adams CL, Ercolano E, Jenkinson MD, Kurian KM, Teo M, Whitfield PC, Sahm F (2021) Fibulin-2: a novel biomarker for differentiating grade II from grade I meningiomas. Int J Mol Sci 22(2):560. https:\/\/doi.org\/10.3390\/ijms22020560","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4715_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep32067","volume":"6","author":"F Zhi","year":"2016","unstructured":"Zhi F, Shao N, Li B, Xue L, Deng D, Xu Y, Lan Q, Peng Y, Yang Y (2016) A serum 6-miRNA panel as a novel non-invasive biomarker for meningioma. Sci Rep 6(1):1. https:\/\/doi.org\/10.1038\/srep32067","journal-title":"Sci Rep"},{"issue":"4","key":"4715_CR198","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1172\/JCI81136","volume":"126","author":"TL Whiteside","year":"2016","unstructured":"Whiteside TL (2016) Exosomes and tumor-mediated immune suppression. J Clin Invest 126(4):1216\u20131223. https:\/\/doi.org\/10.1172\/JCI81136","journal-title":"J Clin Invest"},{"issue":"24","key":"4715_CR199","doi-asserted-by":"publisher","first-page":"1901779","DOI":"10.1002\/advs.201901779","volume":"6","author":"F Xie","year":"2019","unstructured":"Xie F, Zhou X, Fang M, Li H, Su P, Tu Y, Zhang L, Zhou F (2019) Extracellular vesicles in cancer immune microenvironment and cancer immunotherapy. Adv Sci 6(24):1901779. https:\/\/doi.org\/10.1002\/advs.201901779","journal-title":"Adv Sci"},{"issue":"1","key":"4715_CR200","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/1541-7786.MCR-16-0163","volume":"15","author":"S Maji","year":"2017","unstructured":"Maji S, Chaudhary P, Akopova I, Nguyen PM, Hare RJ, Gryczynski I, Vishwanatha JK (2017) Exosomal annexin II promotes angiogenesis and breast cancer metastasisexosomal Anx II in angiogenesis and metastasis. Mol Cancer Res 15(1):93\u2013105. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0163","journal-title":"Mol Cancer Res"},{"issue":"1","key":"4715_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-30446-1","volume":"8","author":"M Chiba","year":"2018","unstructured":"Chiba M, Kubota S, Sato K, Monzen S (2018) Exosomes released from pancreatic cancer cells enhance angiogenic activities via dynamin-dependent endocytosis in endothelial cells in vitro. Sci Rep 8(1):1\u20139. https:\/\/doi.org\/10.1038\/s41598-018-30446-1","journal-title":"Sci Rep"},{"issue":"2","key":"4715_CR202","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3892\/or.2017.5742","volume":"38","author":"HL Lang","year":"2017","unstructured":"Lang HL, Hu GW, Zhang B, Kuang W, Chen Y, Wu L, Xu GH (2017) Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2. Oncol Rep 38(2):785\u2013798. https:\/\/doi.org\/10.3892\/or.2017.5742","journal-title":"Oncol Rep"},{"issue":"8","key":"4715_CR203","doi-asserted-by":"publisher","first-page":"1800158","DOI":"10.1002\/pmic.201800158","volume":"19","author":"A Emmanouilidi","year":"2019","unstructured":"Emmanouilidi A, Paladin D, Greening DW, Falasca M (2019) Oncogenic and non-malignant pancreatic exosome cargo reveal distinct expression of oncogenic and prognostic factors involved in tumor invasion and metastasis. Proteomics 19(8):1800158. https:\/\/doi.org\/10.1002\/pmic.201800158","journal-title":"Proteomics"},{"key":"4715_CR204","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.gene.2018.07.018","volume":"676","author":"M Li","year":"2018","unstructured":"Li M, Lu Y, Xu Y, Wang J, Zhang C, Du Y, Wang L, Li L, Wang B, Shen J, Tang J (2018) Horizontal transfer of exosomal CXCR4 promotes murine hepatocarcinoma cell migration, invasion and lymphangiogenesis. Gene 676:101\u2013109. https:\/\/doi.org\/10.1016\/j.gene.2018.07.018","journal-title":"Gene"},{"issue":"33","key":"4715_CR205","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/onc.2017.100","volume":"36","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zeng C, Zhan Y, Wang H, Jiang X, Li W (2017) Aberrant low expression of p85\u03b1 in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b. Oncogene 36(33):4692\u20134705. https:\/\/doi.org\/10.1038\/onc.2017.100","journal-title":"Oncogene"},{"issue":"6","key":"4715_CR206","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ncb3169","volume":"17","author":"B Costa-Silva","year":"2015","unstructured":"Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J (2015) Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 17(6):816\u2013826. https:\/\/doi.org\/10.1038\/ncb3169","journal-title":"Nat Cell Biol"},{"issue":"3","key":"4715_CR207","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.devcel.2019.04.011","volume":"49","author":"I Wortzel","year":"2019","unstructured":"Wortzel I, Dror S, Kenific CM, Lyden D (2019) Exosome-mediated metastasis: communication from a distance. Develop Cell. 49(3):347\u2013360. https:\/\/doi.org\/10.1016\/j.devcel.2019.04.011","journal-title":"Develop Cell."},{"issue":"1","key":"4715_CR208","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms11150","volume":"7","author":"CL Au Yeung","year":"2016","unstructured":"Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, Schmandt R (2016) Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7(1):1\u20134. https:\/\/doi.org\/10.1038\/ncomms11150","journal-title":"Nat Commun"},{"issue":"3","key":"4715_CR209","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cell.2014.09.051","volume":"159","author":"MC Boelens","year":"2014","unstructured":"Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, Ter Brugge PJ (2014) Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 159(3):499\u2013513. https:\/\/doi.org\/10.1016\/j.cell.2014.09.051","journal-title":"Cell"},{"key":"4715_CR210","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fimmu.2018.00730","volume":"9","author":"FM Barros","year":"2018","unstructured":"Barros FM, Carneiro F, Machado JC, Melo SA (2018) Exosomes and immune response in cancer: friends or foes? Front Immunol 9:730. https:\/\/doi.org\/10.3389\/fimmu.2018.00730","journal-title":"Front Immunol"},{"issue":"10","key":"4715_CR211","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge JE, Gabrilovich DI (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer 13(10):739\u2013752. https:\/\/doi.org\/10.1038\/nrc3581","journal-title":"Nat Rev Cancer"},{"key":"4715_CR212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","volume":"27","author":"H Nishikawa","year":"2014","unstructured":"Nishikawa H, Sakaguchi S (2014) Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 27:1\u20137","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"4715_CR213","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1517\/14712598.2010.529126","volume":"10","author":"E Elkord","year":"2010","unstructured":"Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE (2010) T regulatory cells in cancer: recent advances and therapeutic potential. Exp Opinion Biol Therapy 10(11):1573\u20131586. https:\/\/doi.org\/10.1517\/14712598.2010.529126","journal-title":"Exp Opinion Biol Therapy"},{"key":"4715_CR214","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3389\/fimmu.2019.02453","volume":"10","author":"CM Paluskievicz","year":"2019","unstructured":"Paluskievicz CM, Cao X, Abdi R, Zheng P, Liu Y, Bromberg JS (2019) T regulatory cells and priming the suppressive tumor microenvironment. Front Immunol 10:2453. https:\/\/doi.org\/10.3389\/fimmu.2019.02453","journal-title":"Front Immunol"},{"issue":"7","key":"4715_CR215","doi-asserted-by":"publisher","first-page":"e11469","DOI":"10.1371\/journal.pone.0011469","volume":"5","author":"M Szajnik","year":"2010","unstructured":"Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL (2010) Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE 5(7):e11469. https:\/\/doi.org\/10.1371\/journal.pone.0011469","journal-title":"PLoS ONE"},{"issue":"1","key":"4715_CR216","doi-asserted-by":"publisher","first-page":"36","DOI":"10.7150\/jca.5046","volume":"4","author":"Y Ma","year":"2013","unstructured":"Ma Y, Shurin GV, Peiyuan Z, Shurin MR (2013) Dendritic cells in the cancer microenvironment. J Cancer 4(1):36. https:\/\/doi.org\/10.7150\/jca.5046","journal-title":"J Cancer"},{"key":"4715_CR217","first-page":"14","volume":"92","author":"L Yang","year":"2004","unstructured":"Yang L, Carbone DP (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:14\u201329","journal-title":"Adv Cancer Res"},{"issue":"5","key":"4715_CR218","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3109\/07357907.2013.789905","volume":"31","author":"SH Huang","year":"2013","unstructured":"Huang SH, Li Y, Zhang J, Rong J, Ye S (2013) Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells. Cancer Investig 31(5):330. https:\/\/doi.org\/10.3109\/07357907.2013.789905","journal-title":"Cancer Investig"},{"key":"4715_CR219","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","volume":"17","author":"NR Maimela","year":"2019","unstructured":"Maimela NR, Liu S, Zhang Y (2019) Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J 17:1\u20133. https:\/\/doi.org\/10.1016\/j.csbj.2018.11.004","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"4715_CR220","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.4049\/jimmunol.1700167","volume":"199","author":"H Shinohara","year":"2017","unstructured":"Shinohara H, Kuranaga Y, Kumazaki M, Sugito N, Yoshikawa Y, Takai T, Taniguchi K, Ito Y, Akao Y (2017) Regulated polarization of tumor-associated macrophages by mir-145 via colorectal cancer\u2013derived extracellular vesicles. J Immunol 199(4):1505\u20131515. https:\/\/doi.org\/10.4049\/jimmunol.1700167","journal-title":"J Immunol"},{"issue":"2","key":"4715_CR221","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137\u2013148. https:\/\/doi.org\/10.1016\/j.immuni.2004.07.017","journal-title":"Immunity"},{"key":"4715_CR222","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3389\/fimmu.2019.01563","volume":"10","author":"N Bercovici","year":"2019","unstructured":"Bercovici N, Gu\u00e9rin MV, Trautmann A, Donnadieu E (2019) The remarkable plasticity of macrophages: a chance to fight cancer. Front Immunol 10:1563. https:\/\/doi.org\/10.3389\/fimmu.2019.01563","journal-title":"Front Immunol"},{"issue":"9","key":"4715_CR223","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00432-008-0364-8","volume":"134","author":"L Geng","year":"2008","unstructured":"Geng L, Huang D, Liu J, Qian Y, Deng J, Li D, Hu Z, Zhang J, Jiang G, Zheng S (2008) B7\u2013H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol 134(9):1021\u20131027. https:\/\/doi.org\/10.1007\/s00432-008-0364-8","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"4715_CR224","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/1078-0432.CCR-14-1993","volume":"21","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C, Benson P, Ho TH, Pandite L (2015) Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled TrialPD-L1 correlation with outcome in RCC patients in COMPARZ. Clin Cancer Res 21(5):1071\u20131077. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1993","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4715_CR225","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","volume":"28","author":"CY Mu","year":"2011","unstructured":"Mu CY, Huang JA, Chen Y, Chen C, Zhang XG (2011) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28(3):682\u2013688. https:\/\/doi.org\/10.1007\/s12032-010-9515-2","journal-title":"Med Oncol"},{"issue":"10","key":"4715_CR226","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","volume":"25","author":"K Azuma","year":"2014","unstructured":"Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25(10):1935\u20131940. https:\/\/doi.org\/10.1093\/annonc\/mdu242","journal-title":"Ann Oncol"},{"issue":"3","key":"4715_CR227","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1593\/neo.05733","volume":"8","author":"H Ghebeh","year":"2006","unstructured":"Ghebeh H, Mohammed S, Al-Omair A, Qattant A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Amer SB, Tulbah A, Ajarim D (2006) The B7\u2013H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8(3):190\u2013198. https:\/\/doi.org\/10.1593\/neo.05733","journal-title":"Neoplasia"},{"issue":"4","key":"4715_CR228","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361\u2013370. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0127","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4715_CR229","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","volume":"108","author":"C Wu","year":"2006","unstructured":"Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108(1):19\u201324. https:\/\/doi.org\/10.1016\/j.acthis.2006.01.003","journal-title":"Acta Histochem"},{"key":"4715_CR230","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/DDDT.S75152","volume":"9","author":"Y Qing","year":"2015","unstructured":"Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, Luo H, Yang YX, Dai XY, Zhou SF, Wang D (2015) Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Design Develop Therapy. 9:901. https:\/\/doi.org\/10.2147\/DDDT.S75152","journal-title":"Drug Design Develop Therapy."},{"issue":"3","key":"4715_CR231","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.yexmp.2014.03.005","volume":"96","author":"J Hou","year":"2014","unstructured":"Hou J, Yu Z, Xiang R, Li C, Wang L, Chen S, Li Q, Chen M, Wang L (2014) Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7\u2013H1 in the tumor tissues of gastric cancer. Exp Mol Pathol 96(3):284\u2013291. https:\/\/doi.org\/10.1016\/j.yexmp.2014.03.005","journal-title":"Exp Mol Pathol"},{"issue":"9","key":"4715_CR232","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/modpathol.2016.95","volume":"29","author":"MW Rosenbaum","year":"2016","unstructured":"Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M (2016) PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Modern Pathol 29(9):1104\u20131112. https:\/\/doi.org\/10.1038\/modpathol.2016.95","journal-title":"Modern Pathol"},{"key":"4715_CR233","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1074-3","author":"F Xie","year":"2019","unstructured":"Xie F, Xu M, Lu J, Mao L, Wang S (2019) The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-019-1074-3","journal-title":"Mol Cancer"},{"issue":"12","key":"4715_CR234","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","volume":"18","author":"JR Brahmer","year":"2017","unstructured":"Brahmer JR, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M (2017) Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol 18(12):1600\u20131609. https:\/\/doi.org\/10.1016\/S1470-2045(17)30690-3","journal-title":"Lancet Oncol"},{"key":"4715_CR235","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"1","key":"4715_CR236","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, Britten CD, Dirix L, Lee KW, Taylor M, Sch\u00f6ffski P (2018) Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19(1):51\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(17)30900-2","journal-title":"Lancet Oncol"},{"key":"4715_CR237","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles T, O\u2019Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ et al (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study. JAMA Oncol 3:e172411","journal-title":"JAMA Oncol"},{"key":"4715_CR238","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108\u20132121","journal-title":"N Engl J Med"},{"key":"4715_CR239","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1158\/1078-0432.CCR-19-3014","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S et al (2019) Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37:1470\u20131478. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3014","journal-title":"J Clin Oncol"},{"issue":"19","key":"4715_CR240","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"7","key":"4715_CR241","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19(7):940\u2013952. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6","journal-title":"Lancet Oncol"},{"key":"4715_CR242","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1270\u20131271. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"21","key":"4715_CR243","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006\u20132017. https:\/\/doi.org\/10.1056\/NEJMoa1414428","journal-title":"N Engl J Med"},{"issue":"19","key":"4715_CR244","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824\u20131835. https:\/\/doi.org\/10.1056\/NEJMoa1709030","journal-title":"N Engl J Med"},{"key":"4715_CR245","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bbcan.2018.07.003","volume":"1870","author":"NM Namee","year":"2018","unstructured":"Namee NM, O\u2019Driscoll L (2018) Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer 1870:123\u2013136. https:\/\/doi.org\/10.1016\/j.bbcan.2018.07.003","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"4715_CR246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00848-8","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, Xu L, Jiao Y, Luo S, Li A, Wu K (2020) The role of cancer-derived microRNAs in cancer immune escape. J Hematol Oncol 13(1):1\u20134. https:\/\/doi.org\/10.1186\/s13045-020-00848-8","journal-title":"J Hematol Oncol"},{"key":"4715_CR247","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drup.2018.01.002","volume":"36","author":"RN Gacche","year":"2018","unstructured":"Gacche RN, Assaraf YG (2018) Redundant angiogenic signaling and tumor drug resistance. Drug Res Updates. 36:47\u201376. https:\/\/doi.org\/10.1016\/j.drup.2018.01.002","journal-title":"Drug Res Updates."},{"issue":"3","key":"4715_CR248","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers 6(3):1769\u20131792. https:\/\/doi.org\/10.3390\/cancers6031769","journal-title":"Cancers"},{"issue":"12","key":"4715_CR249","doi-asserted-by":"publisher","first-page":"R663","DOI":"10.1530\/ERC-18-0019","volume":"25","author":"M Alharbi","year":"2018","unstructured":"Alharbi M, Zu\u00f1iga F, Elfeky O, Guanzon D, Lai A, Rice GE, Perrin L, Hooper J, Salomon C (2018) The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. Endocr Relat Cancer 25(12):R663\u2013R685","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"4715_CR250","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ygyno.2007.08.064","volume":"107","author":"S Runz","year":"2007","unstructured":"Runz S, Keller S, Rupp C, Stoeck A, Issa Y, Koensgen D, Mustea A, Sehouli J, Kristiansen G, Altevogt P (2007) Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol 107(3):563\u2013571. https:\/\/doi.org\/10.1016\/j.ygyno.2007.08.064","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4715_CR251","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-9-9","volume":"9","author":"C L\u00e4sser","year":"2011","unstructured":"L\u00e4sser C, Seyed Alikhani V, Ekstr\u00f6m K, Eldh M, Torregrosa Paredes P, Bossios A, Sj\u00f6strand M, Gabrielsson S, L\u00f6tvall J, Valadi H (2011) Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med 9(1):1\u20138. https:\/\/doi.org\/10.1186\/1479-5876-9-9","journal-title":"J Transl Med"},{"issue":"9","key":"4715_CR252","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/sj.ki.5002486","volume":"72","author":"S Keller","year":"2007","unstructured":"Keller S, Rupp C, Stoeck A, Runz S, Fogel M, Lugert S, Hager HD, Abdel-Bakky MS, Gutwein P, Altevogt P (2007) CD24 is a marker of exosomes secreted into urine and amniotic fluid. Kidney Int 72(9):1095\u20131102. https:\/\/doi.org\/10.1038\/sj.ki.5002486","journal-title":"Kidney Int"},{"issue":"12","key":"4715_CR253","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ncb1800","volume":"10","author":"J Skog","year":"2008","unstructured":"Skog J, W\u00fcrdinger T, Van Rijn S, Meijer DH, Gainche L, Curry WT, Carter BS, Krichevsky AM, Breakefield XO (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470\u20131476. https:\/\/doi.org\/10.1038\/ncb1800","journal-title":"Nat Cell Biol"},{"issue":"12","key":"4715_CR254","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1691\/ph.2013.3599","volume":"68","author":"T Yamashita","year":"2013","unstructured":"Yamashita T, Kamada H, Kanasaki S, Maeda Y, Nagano K, Abe Y, Inoue M, Yoshioka Y, Tsutsumi Y, Katayama S, Tsunoda S (2013) Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis. Pharm Int J Pharm Sci 68(12):969\u2013973. https:\/\/doi.org\/10.1691\/ph.2013.3599","journal-title":"Pharm Int J Pharm Sci"},{"key":"4715_CR255","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature14581","volume":"7559","author":"SA Melo","year":"2015","unstructured":"Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C (2015) Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 7559:177\u2013182. https:\/\/doi.org\/10.1038\/nature14581","journal-title":"Nature"},{"key":"4715_CR256","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12371","author":"C Pan","year":"2018","unstructured":"Pan C, Stevic I, Meuller V, Ni Q, Oliveira-Ferrer L, Pantel K, Schwarzenbach H (2018) Exosomal micro RNA s as tumor markers in epithelial ovarian cancer. Mol Oncol. https:\/\/doi.org\/10.1002\/1878-0261.12371","journal-title":"Mol Oncol"},{"key":"4715_CR257","doi-asserted-by":"publisher","first-page":"e0175050","DOI":"10.1371\/journal.pone.0175050","volume":"12","author":"S Fang","year":"2017","unstructured":"Fang S, Tian H, Li X, Jin D, Li X, Kong J, Yang C, Yang X, Lu Y, Luo Y (2017) Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification. PLoS ONE 12:e0175050. https:\/\/doi.org\/10.1371\/journal.pone.0175050","journal-title":"PLoS ONE"},{"key":"4715_CR258","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.02.002","author":"SJ Lee","year":"2021","unstructured":"Lee SJ, Lee J, Jung JH, Park HY, Moon PG, Chae YS et al (2021) Exosomal del-1 as a potent diagnostic marker for breast cancer: prospective cohort study. Clin Breast Cancer. https:\/\/doi.org\/10.1016\/j.clbc.2021.02.002","journal-title":"Clin Breast Cancer"},{"key":"4715_CR259","doi-asserted-by":"publisher","first-page":"7e9","DOI":"10.1016\/j.gdata.2016.05.010","volume":"9","author":"A Ahadi","year":"2016","unstructured":"Ahadi A, Khoury S, Losseva M, Tran N (2016) A comparative analysis of lncRNAs in prostate cancer exosomes and their parental cell lines. Genom Data 9:7e9. https:\/\/doi.org\/10.1016\/j.gdata.2016.05.010","journal-title":"Genom Data"},{"issue":"1","key":"4715_CR260","doi-asserted-by":"publisher","first-page":"20424","DOI":"10.3402\/jev.v2i0.20424","volume":"2","author":"Y Yoshioka","year":"2013","unstructured":"Yoshioka Y, Konishi Y, Kosaka N, Katsuda T, Kato T, Ochiya T (2013) Comparative marker analysis of extracellular vesicles in different human cancer types. J Extracell Vesicles. 2(1):20424. https:\/\/doi.org\/10.3402\/jev.v2i0.20424","journal-title":"J Extracell Vesicles."},{"issue":"2","key":"4715_CR261","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.18632\/oncotarget.20812","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu H, Chen L, Peng Y, Yu S, Liu J, Wu L, Zhang L, Wu Q, Chang X, Yu X, Liu T (2018) Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy. Oncotarget 9(2):2887. https:\/\/doi.org\/10.18632\/oncotarget.20812","journal-title":"Oncotarget"},{"key":"4715_CR262","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.2147\/OTT.S173110","volume":"11","author":"H Gomari","year":"2018","unstructured":"Gomari H, Moghadam MF, Soleimani M (2018) Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle. Onco Targets Ther 11:5753. https:\/\/doi.org\/10.2147\/OTT.S173110","journal-title":"Onco Targets Ther"},{"issue":"5","key":"4715_CR263","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1021\/pr700775x","volume":"7","author":"DM Smalley","year":"2008","unstructured":"Smalley DM, Sheman NE, Nelson K, Theodorescu D (2008) Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res 7(5):2088\u20132096. https:\/\/doi.org\/10.1021\/pr700775x","journal-title":"J Proteome Res"},{"issue":"30","key":"4715_CR264","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O\u2019Briant KC, Allen A, Lin DW (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 105(30):10513\u201310518. https:\/\/doi.org\/10.1073\/pnas.0804549105","journal-title":"Proc Natl Acad Sci"},{"key":"4715_CR265","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fphar.2016.00533","volume":"7","author":"J Wang","year":"2017","unstructured":"Wang J, Zheng Y, Zhao M (2017) Exosome-based cancer therapy: implication for targeting cancer stem cells. Front Pharmacol 7:533. https:\/\/doi.org\/10.3389\/fphar.2016.00533","journal-title":"Front Pharmacol"},{"key":"4715_CR266","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jconrel.2019.08.037","volume":"311","author":"Q Lin","year":"2019","unstructured":"Lin Q, Qu M, Zhou B, Patra HK, Sun Z, Luo Q, Yang W, Wu Y, Zhang Y, Li L, Deng L (2019) Exosome-like nanoplatform modified with targeting ligand improves anti-cancer and anti-inflammation effects of imperialine. J Control Release 311:104\u2013116. https:\/\/doi.org\/10.1016\/j.jconrel.2019.08.037","journal-title":"J Control Release"},{"issue":"5","key":"4715_CR267","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/ange.201912524","volume":"132","author":"W Nie","year":"2020","unstructured":"Nie W, Wu G, Zhang J, Huang LL, Ding J, Jiang A, Zhang Y, Liu Y, Li J, Pu K, Xie HY (2020) Responsive exosome nano-bioconjugates for synergistic cancer therapy. Angewandte Chem 132(5):2034\u20132038. https:\/\/doi.org\/10.1002\/ange.201912524","journal-title":"Angewandte Chem"},{"issue":"5","key":"4715_CR268","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/acs.molpharmaceut.9b00104","volume":"16","author":"JE Pullan","year":"2019","unstructured":"Pullan JE, Confeld MI, Osborn JK, Kim J, Sarkar K, Mallik S (2019) Exosomes as drug carriers for cancer therapy. Mol Pharm 16(5):1789\u20131798. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00104","journal-title":"Mol Pharm"},{"issue":"6","key":"4715_CR269","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.3390\/ijms18061122","volume":"18","author":"KE Gilligan","year":"2017","unstructured":"Gilligan KE, Dwyer RM (2017) Engineering exosomes for cancer therapy. Int J Mol Sci 18(6):1122. https:\/\/doi.org\/10.3390\/ijms18061122","journal-title":"Int J Mol Sci"},{"key":"4715_CR270","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3389\/fimmu.2018.01534","volume":"9","author":"DS Chulpanova","year":"2018","unstructured":"Chulpanova DS, Kitaeva KV, James V, Rizvanov AA, Solovyeva VV (2018) Therapeutic prospects of extracellular vesicles in cancer treatment. Front Immunol 9:1534","journal-title":"Front Immunol"},{"issue":"5","key":"4715_CR271","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/ph6050659","volume":"6","author":"ME Marcus","year":"2013","unstructured":"Marcus ME, Leonard JN (2013) FedExosomes: engineering therapeutic biological nanoparticles that truly deliver. Pharmaceuticals 6(5):659\u2013680. https:\/\/doi.org\/10.3390\/ph6050659","journal-title":"Pharmaceuticals"},{"issue":"7","key":"4715_CR272","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","volume":"35","author":"Y Tian","year":"2014","unstructured":"Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, Wei J, Nie G (2014) A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35(7):2383\u20132390. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.11.083","journal-title":"Biomaterials"},{"issue":"4","key":"4715_CR273","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1021\/acsnano.8b09573","volume":"13","author":"G Yang","year":"2019","unstructured":"Yang G, Chen Q, Wen D, Chen Z, Wang J, Chen G, Wang Z, Zhang X, Zhang Y, Hu Q, Zhang L (2019) A therapeutic microneedle patch made from hair-derived keratin for promoting hair regrowth. ACS Nano 13(4):4354\u20134360. https:\/\/doi.org\/10.1021\/acsnano.8b09573","journal-title":"ACS Nano"},{"key":"4715_CR274","doi-asserted-by":"publisher","first-page":"114788","DOI":"10.1016\/j.taap.2019.114788","volume":"385","author":"KP Maremanda","year":"2019","unstructured":"Maremanda KP, Sundar IK, Rahman I (2019) Protective role of mesenchymal stem cells and mesenchymal stem cell-derived exosomes in cigarette smoke-induced mitochondrial dysfunction in mice. Toxicol Appl Pharmacol 385:114788. https:\/\/doi.org\/10.1016\/j.taap.2019.114788","journal-title":"Toxicol Appl Pharmacol"},{"key":"4715_CR275","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.06.010","author":"S Sheller-Miller","year":"2019","unstructured":"Sheller-Miller S, Choi K, Choi C, Menon R (2019) Cyclic-recombinase-reporter mouse model to determine exosome communication and function during pregnancy. Am J Obstet Gynecol. https:\/\/doi.org\/10.1016\/j.ajog.2019.06.010","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"4715_CR276","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/mt.2012.161","volume":"21","author":"A Mizrak","year":"2013","unstructured":"Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Str\u00f6bel T, Breakefield XO, Saydam O (2013) Genetically engineered microvesicles carrying suicide mRNA\/protein inhibit schwannoma tumor growth. Mol Therapy 21(1):101\u2013108. https:\/\/doi.org\/10.1038\/mt.2012.161","journal-title":"Mol Therapy"},{"issue":"5","key":"4715_CR277","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.nano.2017.03.001","volume":"13","author":"AK Agrawal","year":"2017","unstructured":"Agrawal AK, Aqil F, Jeyabalan J, Spencer WA, Beck J, Gachuki BW, Alhakeem SS, Oben K, Munagala R, Bondada S, Gupta RC (2017) Milk-derived exosomes for oral delivery of paclitaxel. Nanomed Nanotechnol Biol Med 13(5):1627\u20131636. https:\/\/doi.org\/10.1016\/j.nano.2017.03.001","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"4715_CR278","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/mt.2011.164","volume":"19","author":"X Zhuang","year":"2011","unstructured":"Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L et al (2011) Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 19:1769\u20131779","journal-title":"Mol Ther"},{"key":"4715_CR279","doi-asserted-by":"publisher","first-page":"188340","DOI":"10.1016\/j.bbcan.2020.188340","volume":"1873","author":"J Da\u00dfler-Plenker","year":"2020","unstructured":"Da\u00dfler-Plenker J, K\u00fcttner V, Egeblad M (2020) Communication in tiny packages: exosomes as means of tumor-stroma communication. Biochim Biophys Acta Rev Cancer 1873:188340. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188340","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"12","key":"4715_CR280","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.yexcr.2010.04.006","volume":"316","author":"M Guescini","year":"2010","unstructured":"Guescini M, Guidolin D, Vallorani L, Casadei L, Gioacchini AM, Tibollo P, Battistelli M, Falcieri E, Battistin L, Agnati LF, Stocchi V (2010) C2C12 myoblasts release micro-vesicles containing mtDNA and proteins involved in signal transduction. Exp Cell Res 316(12):1977\u20131984. https:\/\/doi.org\/10.1016\/j.yexcr.2010.04.006","journal-title":"Exp Cell Res"},{"issue":"1","key":"4715_CR281","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ncomms1180","volume":"2","author":"L Balaj","year":"2011","unstructured":"Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J (2011) Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2(1):180. https:\/\/doi.org\/10.1038\/ncomms1180","journal-title":"Nat Commun"},{"issue":"7","key":"4715_CR282","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1074\/jbc.C113.532267","volume":"289","author":"C Kahlert","year":"2014","unstructured":"Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, Zhang J, Weitz J, Chin L, Futreal A, Kalluri R (2014) Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 289(7):3869\u20133675. https:\/\/doi.org\/10.1074\/jbc.C113.532267","journal-title":"J Biol Chem"},{"key":"4715_CR283","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax8849","author":"A Yokoi","year":"2019","unstructured":"Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Morey R, Liu J, Roszik J, Clise-Dwyer K, Burks JK (2019) Mechanisms of nuclear content loading to exosomes. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.aax8849","journal-title":"Sci Adv"},{"key":"4715_CR284","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3390\/molecules26092499","volume":"26","author":"OE Andreeva","year":"2021","unstructured":"Andreeva OE, Shchegolev YY, Scherbakov AM et al (2021) Secretion of mutant DNA and mRNA by the exosomes of breast cancer cells. Molecules 26:2499. https:\/\/doi.org\/10.3390\/molecules26092499","journal-title":"Molecules"},{"issue":"3","key":"4715_CR285","first-page":"56","volume":"8","author":"S Kamerkar","year":"2020","unstructured":"Kamerkar S, Burzyn D, Leng C, Burenkova O, Jang SC, Yang R, Boutin A, Kirwin K, Zi T, Dahlberg W, Zhang E (2020) Reprogramming of tumor associated M2 macrophages with antisense oligonucleotide-loaded exosomes results in potent single-agent antitumor activity. Cancer Immunol Res 8(3):56","journal-title":"Cancer Immunol Res"},{"key":"4715_CR286","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","volume":"266","author":"SM Kim","year":"2017","unstructured":"Kim SM, Yang Y, Oh SJ, Hong Y, Seo M, Jang M (2017) Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting. J Control Release 266:8\u201316. https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.013","journal-title":"J Control Release"},{"key":"4715_CR287","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jconrel.2020.04.052","volume":"324","author":"Y Wang","year":"2020","unstructured":"Wang Y, Shahi PK, Xie R, Zhang H, Abdeen AA, Yodsanit N, Ma Z, Saha K, Pattnaik BR, Gong S (2020) A pH-responsive silica\u2013metal\u2013organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries. J Control Release 324:194\u2013203. https:\/\/doi.org\/10.1016\/j.jconrel.2020.04.052","journal-title":"J Control Release"},{"issue":"11","key":"4715_CR288","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41578-019-0145-9","volume":"4","author":"S Tong","year":"2019","unstructured":"Tong S, Moyo B, Lee CM, Leong K, Bao G (2019) Engineered materials for in vivo delivery of genome-editing machinery. Nat Rev Mater 4(11):726\u2013737. https:\/\/doi.org\/10.1038\/s41578-019-0145-9","journal-title":"Nat Rev Mater"},{"issue":"5","key":"4715_CR289","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-17-0827","volume":"17","author":"JH Wang","year":"2018","unstructured":"Wang JH, Forterre AV, Zhao J, Frimannsson DO, Delcayre A, Antes TJ, Efron B, Jeffrey SS, Pegram MD, Matin AC (2018) Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation. Mol Cancer Ther 17(5):1133\u20131142. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0827","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4715_CR290","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1038\/s41467-018-04791-8","volume":"9","author":"WM Usman","year":"2018","unstructured":"Usman WM, Pham TC, Kwok YY, Vu LT, Ma V, Peng B, Chan YS, Wei L, Chin SM, Azad A, He AB (2018) Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun 9(1):2359. https:\/\/doi.org\/10.1038\/s41467-018-04791-8","journal-title":"Nat Commun"},{"issue":"1","key":"4715_CR291","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","volume":"4","author":"Z Yang","year":"2020","unstructured":"Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, Zhao Y, Zhao X, Wang X, Ma Y, Malkoc V (2020) Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng 4(1):69\u201383. https:\/\/doi.org\/10.1038\/s41551-019-0485-1","journal-title":"Nat Biomed Eng"},{"key":"4715_CR292","doi-asserted-by":"publisher","first-page":"119035","DOI":"10.1016\/j.lfs.2021.119035","volume":"269","author":"R Rezaei","year":"2021","unstructured":"Rezaei R, Baghaei K, Amani D, Piccin A, Hashemi SM, Aghdaei HA, Zali MR (2021) Exosome-mediated delivery of functionally active miRNA-375\u20133p mimic regulate epithelial mesenchymal transition (EMT) of colon cancer cells. Life Sci 269:119035. https:\/\/doi.org\/10.1016\/j.lfs.2021.119035","journal-title":"Life Sci"},{"issue":"13","key":"4715_CR293","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.18632\/oncotarget.27531","volume":"11","author":"P Kirave","year":"2020","unstructured":"Kirave P, Gondaliya P, Kulkarni B, Rawal R, Garg R, Jain A, Kalia K (2020) Exosome mediated miR-155 delivery confers cisplatin chemoresistance in oral cancer cells via epithelial-mesenchymal transition. Oncotarget 11(13):1157. https:\/\/doi.org\/10.18632\/oncotarget.27531","journal-title":"Oncotarget"},{"key":"4715_CR294","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2147\/IJN.S154458","volume":"13","author":"G Liang","year":"2018","unstructured":"Liang G, Kan S, Zhu Y, Feng S, Feng W, Gao S (2018) Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells. Int J Nanomed 13:585. https:\/\/doi.org\/10.2147\/IJN.S154458","journal-title":"Int J Nanomed"},{"issue":"1","key":"4715_CR295","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02157-7","volume":"21","author":"W Zhou","year":"2021","unstructured":"Zhou W, Xu M, Wang Z, Yang M (2021) Engineered exosomes loaded with miR-449a selectively inhibit the growth of homologous non-small cell lung cancer. Cancer Cell Int 21(1):1\u20131. https:\/\/doi.org\/10.1186\/s12935-021-02157-7","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4715_CR296","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-019-0563-2","volume":"18","author":"G Liang","year":"2020","unstructured":"Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si K, Sun B, Chen B, Xiao Z (2020) Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnol 18(1):1\u20135. https:\/\/doi.org\/10.1186\/s12951-019-0563-2","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"4715_CR297","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.wneu.2012.01.004","volume":"77","author":"R Yamada","year":"2012","unstructured":"Yamada R, Nakano I (2012) Glioma stem cells: their role in chemoresistance. World Neurosurg 77(2):237\u2013240. https:\/\/doi.org\/10.1016\/j.wneu.2012.01.004","journal-title":"World Neurosurg"},{"key":"4715_CR298","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1038\/mtna.2013.60","volume":"2","author":"JL Munoz","year":"2013","unstructured":"Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P (2013) Delivery of functional anti-miR-9 by mesenchymal stem cell\u2013derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids. 2:e126. https:\/\/doi.org\/10.1038\/mtna.2013.60","journal-title":"Mol Ther Nucleic Acids."},{"key":"4715_CR299","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s11095-014-1593-y","volume":"32","author":"T Yang","year":"2015","unstructured":"Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S (2015) Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res 32:2003\u20132014. https:\/\/doi.org\/10.1007\/s11095-014-1593-y","journal-title":"Pharm Res"},{"key":"4715_CR300","first-page":"1","volume":"5","author":"Y Ren","year":"2016","unstructured":"Ren Y, Ji N, Kang X, Wang R, Ma W, Hu Z, Liu X, Wang Y (2016) Aberrant ceRNA-mediated regulation of KNG1 contributes to glioblastoma-induced angiogenesis. Oncotarget 5:1\u201322","journal-title":"Oncotarget"},{"issue":"7","key":"4715_CR301","doi-asserted-by":"publisher","first-page":"14240","DOI":"10.3390\/ijms140714240","volume":"14","author":"BN Hannafon","year":"2013","unstructured":"Hannafon BN, Ding WQ (2013) Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci 14(7):14240\u201314269. https:\/\/doi.org\/10.3390\/ijms140714240","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4715_CR302","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/01478885.2019.1646984","volume":"42","author":"F Deng","year":"2019","unstructured":"Deng F, Miller J (2019) A review on protein markers of exosome from different bio-resources and the antibodies used for characterization. J Histotechnol 42(4):226\u2013239","journal-title":"J Histotechnol"},{"key":"4715_CR303","doi-asserted-by":"publisher","first-page":"42","DOI":"10.20517\/2394-4722.2020.79","volume":"6","author":"A Von Schulze","year":"2020","unstructured":"Von Schulze A, Deng F (2020) A review on exosome-based cancer therapy. J Cancer Metastasis Treat 6:42. https:\/\/doi.org\/10.20517\/2394-4722.2020.79","journal-title":"J Cancer Metastasis Treat"},{"issue":"4","key":"4715_CR304","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1586\/14789450.2015.1055324","volume":"12","author":"M Bruschi","year":"2015","unstructured":"Bruschi M, Ravera S, Santucci L, Candiano G, Bartolucci M, Calzia D, Lavarello C, Inglese E, Petretto A, Ghiggeri G, Panfoli I (2015) The human urinary exosome as a potential metabolic effector cargo. Exp Rev Proteomics. 12(4):425\u2013432. https:\/\/doi.org\/10.1586\/14789450.2015.1055324","journal-title":"Exp Rev Proteomics."},{"issue":"1","key":"4715_CR305","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2013.02.019","volume":"335","author":"M Katakowski","year":"2013","unstructured":"Katakowski M, Buller B, Zheng X, Lu Y, Rogers T, Osobamiro O, Shu W, Jiang F, Chopp M (2013) Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett 335(1):201\u2013204. https:\/\/doi.org\/10.1016\/j.canlet.2013.02.019","journal-title":"Cancer Lett"},{"issue":"1","key":"4715_CR306","doi-asserted-by":"publisher","first-page":"411","DOI":"10.7150\/thno.33482","volume":"10","author":"K Zhang","year":"2020","unstructured":"Zhang K, Dong C, Chen M, Yang T, Wang X, Gao Y, Wang L, Wen Y, Chen G, Wang X, Yu X (2020) Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma. Theranostics 10(1):411. https:\/\/doi.org\/10.7150\/thno.33482","journal-title":"Theranostics"},{"issue":"3","key":"4715_CR307","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/hep.29586","volume":"67","author":"F Wang","year":"2018","unstructured":"Wang F, Li L, Piontek K, Sakaguchi M, Selaru FM (2018) Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology 67(3):940\u2013954. https:\/\/doi.org\/10.1002\/hep.29586","journal-title":"Hepatology"},{"key":"4715_CR308","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1038\/s41388-017-0116-9","volume":"37","author":"KP O\u2019brien","year":"2018","unstructured":"O\u2019brien KP, Khan S, Gilligan KE, Zafar H, Lalor P, Glynn C, O\u2019Flatharta C, Ingoldsby H, Dockery P, De Bhulbh A et al (2018) Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379. Oncogene 37:2137\u20132149","journal-title":"Oncogene"},{"key":"4715_CR309","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.canlet.2018.10.039","volume":"442","author":"Y Ding","year":"2019","unstructured":"Ding Y, Cao F, Sun H, Wang Y, Liu S, Wu Y, Cui Q, Mei W, Li F (2019) Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145\u20135p to inhibit pancreatic ductal adenocarcinoma progression. Cancer Lett 442:351\u2013361. https:\/\/doi.org\/10.1016\/j.canlet.2018.10.039","journal-title":"Cancer Lett"},{"issue":"1","key":"4715_CR310","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-07810-w","volume":"9","author":"Z Zeng","year":"2018","unstructured":"Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, Zhou K, Liu X, Ren X, Wang F, Hu J (2018) Cancer-derived exosomal miR-25\u20133p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun 9(1):1\u20134. https:\/\/doi.org\/10.1038\/s41467-018-07810-w","journal-title":"Nat Commun"},{"issue":"15","key":"4715_CR311","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1158\/0008-5472.CAN-10-4076","volume":"71","author":"RB Rountree","year":"2011","unstructured":"Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, Brinkmann K, Dirmeier U, Laus R, Delcayre A (2011) Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacyexosome targeting of tumor antigens improves efficacy. Cancer Res 71(15):5235\u20135244. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-4076","journal-title":"Cancer Res"},{"issue":"10","key":"4715_CR312","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3390\/cancers13102397","volume":"13","author":"K Kaban","year":"2021","unstructured":"Kaban K, Hinterleitner C, Zhou Y, Salva E, Kantarci AG, Salih HR, M\u00e4rklin M (2021) Therapeutic silencing of BCL-2 using NK cell-derived exosomes as a novel therapeutic approach in breast cancer. Cancers 13(10):2397. https:\/\/doi.org\/10.3390\/cancers13102397","journal-title":"Cancers"},{"key":"4715_CR313","doi-asserted-by":"publisher","first-page":"241.e1","DOI":"10.1016\/j.urology.2016.01.028","volume":"91","author":"KA Greco","year":"2016","unstructured":"Greco KA, Franzen CA, Foreman KE, Flanigan RC, Kuo PC, Gupta GN (2016) PLK-1 silencing in bladder cancer by siRNA delivered with exosomes. Urology 91:241.e1. https:\/\/doi.org\/10.1016\/j.urology.2016.01.028","journal-title":"Urology"},{"key":"4715_CR314","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-018-0429-z","volume":"16","author":"H Li","year":"2018","unstructured":"Li H, Yang C, Shi Y, Zhao L (2018) Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma. J Nanobiotechnol 16:1\u20133. https:\/\/doi.org\/10.1186\/s12951-018-0429-z","journal-title":"J Nanobiotechnol"},{"key":"4715_CR315","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/IJN.S231214","volume":"1","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Zhang H, Ning T, Liu D, Deng T, Liu R, Bai M, Zhu K, Li J, Fan Q, Ying G (2020) Exosome-delivered c-Met siRNA could reverse chemoresistance to cisplatin in gastric cancer. Int J Nanomed 1:2323\u20132335. https:\/\/doi.org\/10.2147\/IJN.S231214","journal-title":"Int J Nanomed"},{"issue":"12","key":"4715_CR316","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1002\/1878-0261.13052","volume":"15","author":"D Lin","year":"2021","unstructured":"Lin D, Zhang H, Liu R, Deng T, Ning T, Bai M, Yang Y, Zhu K, Wang J, Duan J, Ge S (2021) iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation. Mol Oncol 15(12):3430\u20133446. https:\/\/doi.org\/10.1002\/1878-0261.13052","journal-title":"Mol Oncol"},{"key":"4715_CR317","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.bbadis.2016.12.018","volume":"3","author":"J Xue","year":"1863","unstructured":"Xue J, Liu Y, Luo F, Lu X, Xu H, Liu X, Lu L, Yang Q, Chen C, Fan W (1863) Liu Q (2017) Circ100284, via miR-217 regulation of EZH2, is involved in the arsenite-accelerated cell cycle of human keratinocytes in carcinogenesis. Biochim Biophys Acta Mol Basis Dis 3:753\u2013763. https:\/\/doi.org\/10.1016\/j.bbadis.2016.12.018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"5","key":"4715_CR318","first-page":"959","volume":"21","author":"HL Lang","year":"2017","unstructured":"Lang HL, Hu GW, Chen Y, Liu Y, Tu W, Lu YM, Wu L, Xu GH (2017) Glioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3. Eur Rev Med Pharmacol Sci 21(5):959\u2013972","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4715_CR319","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0880-3","volume":"17","author":"R Zheng","year":"2018","unstructured":"Zheng R, Du M, Wang X, Xu W, Liang J, Wang W, Lv Q, Qin C, Chu H, Wang M, Yuan L (2018) Exosome\u2013transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression. Mol Cancer 17:1\u20133. https:\/\/doi.org\/10.1186\/s12943-018-0880-3","journal-title":"Mol Cancer"},{"issue":"4","key":"4715_CR320","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.4049\/jimmunol.172.4.2126","volume":"172","author":"F Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T (2004) Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I\/peptide complexes to dendritic cells. J Immunol 172(4):2126\u20132136. https:\/\/doi.org\/10.4049\/jimmunol.172.4.2126","journal-title":"J Immunol"},{"issue":"4","key":"4715_CR321","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.4049\/jimmunol.172.4.2137","volume":"172","author":"N Chaput","year":"2004","unstructured":"Chaput N, Schartz NE, Andr\u00e9 F, Ta\u00efeb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G (2004) Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 172(4):2137\u20132146. https:\/\/doi.org\/10.4049\/jimmunol.172.4.2137","journal-title":"J Immunol"},{"issue":"6","key":"4715_CR322","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3(6):673\u2013682. https:\/\/doi.org\/10.1016\/1074-7613(95)90057-8","journal-title":"Immunity"},{"issue":"22","key":"4715_CR323","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271(22):12687\u201312690. https:\/\/doi.org\/10.1074\/jbc.271.22.12687","journal-title":"J Biol Chem"},{"issue":"12","key":"4715_CR324","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00109-006-0102-0","volume":"84","author":"S Dai","year":"2006","unstructured":"Dai S, Zhou X, Wang B, Wang Q, Fu Y, Chen T, Wan T, Yu Y, Cao X (2006) Enhanced induction of dendritic cell maturation and HLA-A* 0201-restricted CEA-specific CD8+ CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J Mol Med 84(12):1067\u20131076. https:\/\/doi.org\/10.1007\/s00109-006-0102-0","journal-title":"J Mol Med"},{"issue":"4","key":"4715_CR325","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ijc.20757","volume":"114","author":"JA Cho","year":"2005","unstructured":"Cho JA, Yeo DJ, Son HY, Kim HW, Jung DS, Ko JK, Koh JS, Kim YN, Kim CW (2005) Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int J cancer 114(4):613\u2013622. https:\/\/doi.org\/10.1002\/ijc.20757","journal-title":"Int J cancer"},{"issue":"1","key":"4715_CR326","doi-asserted-by":"publisher","first-page":"31053","DOI":"10.3402\/jev.v5.31053","volume":"5","author":"SA Kooijmans","year":"2016","unstructured":"Kooijmans SA, Aleza CG, Roffler SR, van Solinge WW, Vader P, Schiffelers RM (2016) Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J Extracell Vesicles. 5(1):31053. https:\/\/doi.org\/10.3402\/jev.v5.31053","journal-title":"J Extracell Vesicles."},{"issue":"3","key":"4715_CR327","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10571-015-0309-0","volume":"36","author":"J Hall","year":"2016","unstructured":"Hall J, Prabhakar S, Balaj L, Lai CP, Cerione RA, Breakefield XO (2016) Delivery of therapeutic proteins via extracellular vesicles: review and potential treatments for Parkinson\u2019s disease, glioma, and schwannoma. Cell Mol Neurobiol 36(3):417\u2013427. https:\/\/doi.org\/10.1007\/s10571-015-0309-0","journal-title":"Cell Mol Neurobiol"},{"issue":"13","key":"4715_CR328","doi-asserted-by":"publisher","first-page":"8166","DOI":"10.1074\/jbc.M114.621383","volume":"290","author":"ME Hung","year":"2015","unstructured":"Hung ME, Leonard JN (2015) Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem 290(13):8166\u20138172. https:\/\/doi.org\/10.1074\/jbc.M114.621383","journal-title":"J Biol Chem"},{"issue":"1","key":"4715_CR329","doi-asserted-by":"publisher","first-page":"23743","DOI":"10.3402\/jev.v3.23743","volume":"3","author":"L Cheng","year":"2014","unstructured":"Cheng L, Sharples RA, Scicluna BJ, Hill AF (2014) Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles 3(1):23743. https:\/\/doi.org\/10.3402\/jev.v3.23743","journal-title":"J Extracell Vesicles"},{"issue":"5","key":"4715_CR330","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1166\/jbn.2016.2229","volume":"12","author":"H Malhotra","year":"2016","unstructured":"Malhotra H, Sheokand N, Kumar S, Chauhan AS, Kumar M, Jakhar P, Boradia VM, Raje CI, Raje M (2016) Exosomes: tunable nano vehicles for macromolecular delivery of transferrin and lactoferrin to specific intracellular compartment. J Biomed Nanotechnol 12(5):1101\u20131114. https:\/\/doi.org\/10.1166\/jbn.2016.2229","journal-title":"J Biomed Nanotechnol"},{"key":"4715_CR331","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/971907","author":"RC Lai","year":"2012","unstructured":"Lai RC, Tan SS, Teh BJ, Sze SK, Arslan F, De Kleijn DP, Choo A, Lim SK (2012) Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics. https:\/\/doi.org\/10.1155\/2012\/971907","journal-title":"Int J Proteomics"},{"issue":"8","key":"4715_CR332","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.21873\/anticanres.13561","volume":"39","author":"T Satake","year":"2019","unstructured":"Satake T, Suetsugu A, Nakamura M, Kunisada T, Saji S, Moriwaki H, Shimizu M, Hoffman RM (2019) Color-coded imaging of the fate of cancer-cell-derived exosomes during pancreatic cancer metastases in a nude-mouse model. Anticancer Res 39(8):4055\u20134060. https:\/\/doi.org\/10.21873\/anticanres.13561","journal-title":"Anticancer Res"},{"issue":"17","key":"4715_CR333","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1093\/nar\/gks463","volume":"40","author":"J Wahlgren","year":"2012","unstructured":"Wahlgren J, Karlson TD, Brisslert M, Vaziri Sani F, Telemo E, Sunnerhagen P, Valadi H (2012) Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 40(17):e130. https:\/\/doi.org\/10.1093\/nar\/gks463","journal-title":"Nucleic Acids Res"},{"key":"4715_CR334","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.07.011","volume":"142","author":"D Yuan","year":"2017","unstructured":"Yuan D, Zhao Y, Banks WA, Bullock KM, Haney M, Batrakova E, Kabanov AV (2017) Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials 142:1\u20132. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.07.011","journal-title":"Biomaterials"},{"key":"4715_CR335","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymeth.2015.05.028","volume":"87","author":"N Zarovni","year":"2015","unstructured":"Zarovni N, Corrado A, Guazzi P, Zocco D, Lari E, Radano G, Muhhina J, Fondelli C, Gavrilova J, Chiesi A (2015) Integrated isolation and quantitative analysis of exosome shuttled proteins and nucleic acids using immunocapture approaches. Methods 87:46\u201358. https:\/\/doi.org\/10.1016\/j.ymeth.2015.05.028","journal-title":"Methods"},{"key":"4715_CR336","doi-asserted-by":"publisher","first-page":"9329","DOI":"10.2147\/OTT.S229494","volume":"12","author":"P Tang","year":"2019","unstructured":"Tang P, Tao L, Yuan C, Zhang L, Xiu D (2019) Serum derived exosomes from pancreatic cancer patients promoted metastasis: an iTRAQ-based proteomic analysis. Onco Targets Ther 12:9329. https:\/\/doi.org\/10.2147\/OTT.S229494","journal-title":"Onco Targets Ther"},{"issue":"13","key":"4715_CR337","doi-asserted-by":"publisher","first-page":"1800394","DOI":"10.1002\/pmic.201800394","volume":"19","author":"S Han","year":"2019","unstructured":"Han S, Huo Z, Nguyen K, Zhu F, Underwood PW, Basso KB, George TJ, Hughes SJ (2019) The proteome of pancreatic cancer-derived exosomes reveals signatures rich in key signaling pathways. Proteomics 19(13):1800394. https:\/\/doi.org\/10.1002\/pmic.201800394","journal-title":"Proteomics"},{"issue":"5","key":"4715_CR338","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm0598-594","volume":"5","author":"L Zitvogel","year":"1998","unstructured":"Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes. Nat Med 5(5):594\u2013600. https:\/\/doi.org\/10.1038\/nm0598-594","journal-title":"Nat Med"},{"key":"4715_CR339","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semcdb.2016.12.001","volume":"67","author":"OY Kim","year":"2017","unstructured":"Kim OY, Lee J, Gho YS (2017) Extracellular vesicle mimetics: novel alternatives to extracellular vesicle-based theranostics, drug delivery, and vaccines. Semin Cell Develop Biol 67:74\u201382. https:\/\/doi.org\/10.1016\/j.semcdb.2016.12.001","journal-title":"Semin Cell Develop Biol"},{"issue":"2","key":"4715_CR340","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/ijn.s596","volume":"3","author":"WH De Jong","year":"2008","unstructured":"De Jong WH, Borm PJ (2008) Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 3(2):133. https:\/\/doi.org\/10.2147\/ijn.s596","journal-title":"Int J Nanomed"},{"issue":"5","key":"4715_CR341","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1734-1140(12)70901-5","volume":"64","author":"AZ Wilczewska","year":"2012","unstructured":"Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H (2012) Nanoparticles as drug delivery systems. Pharmacol Rep 64(5):1020\u20131037. https:\/\/doi.org\/10.1016\/S1734-1140(12)70901-5","journal-title":"Pharmacol Rep"},{"key":"4715_CR342","doi-asserted-by":"publisher","first-page":"108032","DOI":"10.1016\/j.carres.2020.108032","volume":"493","author":"D Li","year":"2020","unstructured":"Li D, Yao S, Zhou Z, Shi J, Huang Z, Wu Z (2020) Hyaluronan decoration of milk exosomes directs tumor-specific delivery of doxorubicin. Carbohydrate Res 493:108032. https:\/\/doi.org\/10.1016\/j.carres.2020.108032","journal-title":"Carbohydrate Res"},{"issue":"1","key":"4715_CR343","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nano.2017.09.011","volume":"14","author":"MS Kim","year":"2018","unstructured":"Kim MS, Haney MJ, Zhao Y, Yuan D, Deygen I, Klyachko NL, Kabanov AV, Batrakova EV (2018) Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomed Nanotechnol Biol Med 14(1):195\u2013204. https:\/\/doi.org\/10.1016\/j.nano.2017.09.011","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"1","key":"4715_CR344","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.yexmp.2016.05.013","volume":"101","author":"F Aqil","year":"2016","unstructured":"Aqil F, Kausar H, Agrawal AK, Jeyabalan J, Kyakulaga AH, Munagala R, Gupta R (2016) Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp Mol Pathol 101(1):12\u201321. https:\/\/doi.org\/10.1016\/j.yexmp.2016.05.013","journal-title":"Exp Mol Pathol"},{"key":"4715_CR345","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.canlet.2017.02.004","volume":"393","author":"R Munagala","year":"2017","unstructured":"Munagala R, Aqil F, Jeyabalan J, Agrawal AK, Mudd AM, Kyakulaga AH, Singh IP, Vadhanam MV, Gupta RC (2017) Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett 393:94\u2013102. https:\/\/doi.org\/10.1016\/j.canlet.2017.02.004","journal-title":"Cancer Lett"},{"issue":"6","key":"4715_CR346","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s11095-014-1593-y","volume":"32","author":"T Yang","year":"2015","unstructured":"Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S (2015) Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res 32(6):2003\u20132014. https:\/\/doi.org\/10.1007\/s11095-014-1593-y","journal-title":"Pharm Res"},{"issue":"9","key":"4715_CR347","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/mt.2010.105","volume":"18","author":"D Sun","year":"2010","unstructured":"Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang HG (2010) A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 18(9):1606\u20131614. https:\/\/doi.org\/10.1038\/mt.2010.105","journal-title":"Mol Ther"},{"issue":"11","key":"4715_CR348","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1039\/C7FO00882A","volume":"8","author":"F Aqil","year":"2017","unstructured":"Aqil F, Jeyabalan J, Agrawal AK, Kyakulaga AH, Munagala R, Parker L, Gupta RC (2017) Exosomal delivery of berry anthocyanidins for the management of ovarian cancer. Food Funct 8(11):4100\u20134107","journal-title":"Food Funct"},{"issue":"18","key":"4715_CR349","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA (2014) How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell 25(18):2677\u20132681. https:\/\/doi.org\/10.1091\/mbc.e14-04-0916","journal-title":"Mol Biol Cell"},{"issue":"220","key":"4715_CR350","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jconrel.2015.09.031","volume":"28","author":"H Saari","year":"2015","unstructured":"Saari H, L\u00e1zaro-Ib\u00e1\u00f1ez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M (2015) Microvesicle-and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J Control Release 28(220):727\u2013737. https:\/\/doi.org\/10.1016\/j.jconrel.2015.09.031","journal-title":"J Control Release"},{"issue":"7","key":"4715_CR351","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.nano.2018.05.020","volume":"14","author":"Y Li","year":"2018","unstructured":"Li Y, Gao Y, Gong C, Wang Z, Xia Q, Gu F, Hu C, Zhang L, Guo H, Gao S (2018) A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer. Nanomed Nanotechnol Biol Med 14(7):1973\u20131985. https:\/\/doi.org\/10.1016\/j.nano.2018.05.020","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"15","key":"4715_CR352","doi-asserted-by":"publisher","first-page":"12341","DOI":"10.1021\/acsami.7b18135","volume":"10","author":"Z Ye","year":"2018","unstructured":"Ye Z, Zhang T, He W, Jin H, Liu C, Yang Z, Ren J (2018) Methotrexate-loaded extracellular vesicles functionalized with therapeutic and targeted peptides for the treatment of glioblastoma multiforme. ACS Appl Mater Interfaces 10(15):12341\u201312350. https:\/\/doi.org\/10.1021\/acsami.7b18135","journal-title":"ACS Appl Mater Interfaces"},{"issue":"101","key":"4715_CR353","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.actbio.2019.10.022","volume":"1","author":"YJ Li","year":"2020","unstructured":"Li YJ, Wu JY, Wang JM, Hu XB, Cai JX, Xiang DX (2020) Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer. Acta Biomater 1(101):519\u2013530. https:\/\/doi.org\/10.1016\/j.actbio.2019.10.022","journal-title":"Acta Biomater"},{"issue":"12","key":"4715_CR354","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nrc948","volume":"2","author":"CE Antonio","year":"2002","unstructured":"Antonio CE (2002) Oncolytic viruses. Nat Rev Cancer 2(12):938\u2013950. https:\/\/doi.org\/10.1038\/nrc948","journal-title":"Nat Rev Cancer"},{"issue":"283","key":"4715_CR355","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jconrel.2018.05.015","volume":"10","author":"M Garofalo","year":"2018","unstructured":"Garofalo M, Saari H, Somersalo P, Crescenti D, Kuryk L, Aksela L, Capasso C, Madetoja M, Koskinen K, Oksanen T, M\u00e4kitie A (2018) Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. J Control Release 10(283):223\u2013234. https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.015","journal-title":"J Control Release"},{"issue":"1","key":"4715_CR356","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2015.10.020","volume":"371","author":"R Munagala","year":"2016","unstructured":"Munagala R, Aqil F, Jeyabalan J, Gupta RC (2016) Bovine milk-derived exosomes for drug delivery. Cancer Lett 371(1):48\u201361. https:\/\/doi.org\/10.1016\/j.canlet.2015.10.020","journal-title":"Cancer Lett"},{"issue":"15","key":"4715_CR357","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.isci.2019.05.004","volume":"31","author":"M Ullah","year":"2019","unstructured":"Ullah M, Liu DD, Thakor AS (2019) Mesenchymal stromal cell homing: mechanisms and strategies for improvement. Iscience 31(15):421\u2013438. https:\/\/doi.org\/10.1016\/j.isci.2019.05.004","journal-title":"Iscience"},{"issue":"4","key":"4715_CR358","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/ijc.31792","volume":"144","author":"U Altanerova","year":"2019","unstructured":"Altanerova U, Jakubechova J, Benejova K, Priscakova P, Pesta M, Pitule P, Topolcan O, Kausitz J, Zduriencikova M, Repiska V, Altaner C (2019) Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes. Int J Cancer 144(4):897\u2013908. https:\/\/doi.org\/10.1002\/ijc.31792","journal-title":"Int J Cancer"},{"issue":"6","key":"4715_CR359","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","volume":"164","author":"M Tkach","year":"2016","unstructured":"Tkach M, Th\u00e9ry C (2016) Communication by extracellular vesicles: where we are and where we need to go. Cell 164(6):1226\u20131232. https:\/\/doi.org\/10.1016\/j.cell.2016.01.043","journal-title":"Cell"},{"issue":"3","key":"4715_CR360","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1021\/acs.nanolett.0c04753","volume":"21","author":"W Niu","year":"2021","unstructured":"Niu W, Xiao Q, Wang X, Zhu J, Li J, Liang X, Peng Y, Wu C, Lu R, Pan Y, Luo J (2021) A biomimetic drug delivery system by integrating grapefruit extracellular vesicles and doxorubicin-loaded heparin-based nanoparticles for glioma therapy. Nano Lett 21(3):1484\u20131492. https:\/\/doi.org\/10.1021\/acs.nanolett.0c04753","journal-title":"Nano Lett"},{"issue":"4","key":"4715_CR361","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.18632\/oncotarget.23321","volume":"9","author":"J Shen","year":"2018","unstructured":"Shen J, Hu Y, Putt KS, Singhal S, Han H, Visscher DW, Murphy LM, Low PS (2018) Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget 9(4):4485. https:\/\/doi.org\/10.18632\/oncotarget.23321","journal-title":"Oncotarget"},{"issue":"3","key":"4715_CR362","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1021\/cr050247k","volume":"106","author":"R Stern","year":"2006","unstructured":"Stern R, Jedrzejas MJ (2006) Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 106(3):818\u2013839. https:\/\/doi.org\/10.1021\/cr050247k","journal-title":"Chem Rev"},{"issue":"105","key":"4715_CR363","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biomaterials.2016.07.003","volume":"1","author":"DC Watson","year":"2016","unstructured":"Watson DC, Bayik D, Srivatsan A, Bergamaschi C, Valentin A, Niu G, Bear J, Monninger M, Sun M, Morales-Kastresana A, Jones JC (2016) Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials 1(105):195\u2013205. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.07.003","journal-title":"Biomaterials"},{"issue":"1","key":"4715_CR364","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep21933","volume":"6","author":"YT Sato","year":"2016","unstructured":"Sato YT, Umezaki K, Sawada S, Mukai SA, Sasaki Y, Harada N, Shiku H, Akiyoshi K (2016) Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep 6(1):1\u20131. https:\/\/doi.org\/10.1038\/srep21933","journal-title":"Sci Rep"},{"issue":"207","key":"4715_CR365","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2015.03.033","volume":"10","author":"MJ Haney","year":"2015","unstructured":"Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, Patel T, Piroyan A, Sokolsky M, Kabanov AV, Batrakova EV (2015) Exosomes as drug delivery vehicles for Parkinson\u2019s disease therapy. J Control Release 10(207):18\u201330. https:\/\/doi.org\/10.1016\/j.jconrel.2015.03.033","journal-title":"J Control Release"},{"issue":"287","key":"4715_CR366","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jconrel.2018.08.035","volume":"10","author":"M Qu","year":"2018","unstructured":"Qu M, Lin Q, Huang L, Fu Y, Wang L, He S, Fu Y, Yang S, Zhang Z, Zhang L, Sun X (2018) Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson\u2019s disease. J Control Release 10(287):156\u2013166. https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.035","journal-title":"J Control Release"},{"issue":"7","key":"4715_CR367","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.omtn.2017.04.010","volume":"16","author":"J Yang","year":"2017","unstructured":"Yang J, Zhang X, Chen X, Wang L, Yang G (2017) Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia. Molr Ther Nucleic Acids 16(7):278\u2013287. https:\/\/doi.org\/10.1016\/j.omtn.2017.04.010","journal-title":"Molr Ther Nucleic Acids"},{"issue":"2","key":"4715_CR368","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1208\/s12248-016-0015-y","volume":"19","author":"T Yang","year":"2017","unstructured":"Yang T, Fogarty B, LaForge B, Aziz S, Pham T, Lai L, Bai S (2017) Delivery of small interfering RNA to inhibit vascular endothelial growth factor in zebrafish using natural brain endothelia cell-secreted exosome nanovesicles for the treatment of brain cancer. AAPS J 19(2):475\u2013486. https:\/\/doi.org\/10.1208\/s12248-016-0015-y","journal-title":"AAPS J"},{"issue":"317","key":"4715_CR369","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jconrel.2019.11.009","volume":"10","author":"G Kim","year":"2020","unstructured":"Kim G, Kim M, Lee Y, Byun JW, Lee M (2020) Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes. J Control Release 10(317):273\u2013281. https:\/\/doi.org\/10.1016\/j.jconrel.2019.11.009","journal-title":"J Control Release"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-023-04715-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-023-04715-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-023-04715-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:08:47Z","timestamp":1744171727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-023-04715-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":369,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["4715"],"URL":"https:\/\/doi.org\/10.1007\/s11010-023-04715-1","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) confirm that this article content has no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}